

Scientific programme – overview

Tuesday 21 October		Wednesday 22 October			
ROOM ABC		ROOM A	ROOM B	ROOM C	
		08.00	Workshop 1 Animal models in drug development	Workshop 2 Pharmacogenomics-where are we now?	Workshop 3 Paedatric oncology
		09.45	Coffee Break		
		10.15	Workshop 4 Phase 0 trials-are they necessary?	Workshop 5 Targeting CYP pathway	Workshop 6 Design and conduct of phase II trials for targeted agents
12.00	Lunch	12.00	Lunch/Poster session		
13.10	Opening Ceremony	14.15	Keynote Lecture RECIST 1.1		
13.15	Michel Clavel lecture No Risk, No fun	15.00	Plenary session 2 Proffered papers		
14.00	Keynote lecture IGF as a target	16.00	Coffee Break		
14.45	Coffee Break	16.30	Plenary session 3 Molecular targets-state of the science B		
15.15	Plenary session 1 Molecular targets-state of the science A	18.15	Plenary session 3 Molecular targets-state of the science B		
17.00	Welcome reception				

Posters

Angiogenesis
 Animal models
 Biomarkers
 Chemoprevention
 Drug delivery
 Drug screening
 Heat shock proteins
 Hormonal agents
 Metastasis and invasion
 Natural products and marine compounds
 Paediatric - early drug development
 Pharmacogenomics
 Phase II
 PI3Kinase
 Proteasome

Thursday 23 October		Friday 24 October	
ROOM ABC		ROOM ABC	
08.00	Plenary session 4 Targeting autophagic pathways	08.00	Plenary session 8 RNA based technologies for target identification, validation and treatment
09.45	Coffee Break	09.45	Coffee Break
10.15	Plenary session 5 Molecular targets-state of the science C	10.15	Plenary session 9 Imaging molecular targets
12.00	Lunch/Poster session	12.00	Lunch/Poster session
14.30	Plenary session 6 Proffered papers	14.00	Plenary session 10 Challenges in the development of antibodies and antibody conjugates
16.00	Coffee Break	15.45	
16.30	Plenary session 7 Targeting protein translation and protein-protein interaction in cancer	15.50	Closing ceremony
18.15	Get together Party		

Posters

Apoptosis, necrosis, autophagy
Aurora kinase
Cyclins and CDK's
Gene therapy and antisense approaches
Her
mTOR
New molecular targets
Phase I
Polo kinase
Protein - protein interaction
Telomerase - targeting agents
Tubulin - interacting agents

Posters

Antimetabolites
Bioreductive agents
Differentiation
DNA repair
Drug resistance and modifiers
Monoclonal antibodies and targeted toxins/nuclides
Radiation interactive agents
RNA and RNA based technologies
Signal transduction modulators
Topoisomerase inhibitors
Vaccines

Scientific programme – details

Tuesday, 21 October 2008

Opening Ceremony		Room ABC
13:00–13:10	Opening remarks <i>M. Piccart</i> EORTC <i>J. Doroshow</i> NCI <i>W.N. Hait</i> AACR	
Michel Clavel lecture		Room ABC
Chair: P. Schöffski (Leuven, Belgium)		Abstract number
13:15–14:00	No risk, no fun <i>J. Verweij (Rotterdam, The Netherlands)</i>	1
Keynote lecture		Room ABC
Chair: J. Doroshow (Bethesda, USA)		Abstract number
14:00–14:45	IGF-I as an emerging target <i>D. Yee (Minneapolis, USA)</i>	2
Plenary session 1		Room ABC
		Abstract number
15:15–17:00	Molecular targets – state of the science A Chairs: C.J.A. Punt (Nijmegen, The Netherlands) and A.J. Murgo (Bethesda, USA)	
15:15	RET inhibition: therapeutic implications in thyroid cancer <i>D.G. Pfister (New York, USA)</i>	3
15:40	C-Met as a target in clinical oncology; rationale and current achievements <i>F.A.L.M. Eskens (Rotterdam, The Netherlands)</i>	4
16:05	Biological roles of PI 3-kinase isoforms <i>B. Vanhaesebroeck (London, United Kingdom)</i>	5
16:30	Notch as a potential therapeutic target in cancer <i>L. Miele (Illinois, USA)</i>	6

Wednesday, 22 October 2008

Workshop 1		Room A
		Abstract number
08:00–09:45	Animal models in drug development Chairs: J.L. Abbruzzese (Houston, USA) and G. Adolf (Vienna, Austria)	
08:00	Developing combination therapies for hormone-refractory prostate cancer in a pre-clinical mouse model of the disease <i>C. Abate-Shen (New York, USA)</i>	7
08:25	Pitfalls for cancer drug discovery with “genetic” animal models <i>E. Sausville (Baltimore, USA)</i>	8
08:50	How naturally occurring cancers in dogs can inform the drug development path <i>C. Khanna (Bethesda, USA)</i>	9
09:15	Imaging signaling pathways in animal models <i>A. Rehemtulla (Ann Arbor, USA)</i>	10
Workshop 2		Room B
		Abstract number
08:00–09:45	Paediatric Oncology Chairs: M. Smith (Rockville, USA) and G. Vassal (Villejuif, France)	
08:00	Update on the application of the EU paediatric regulation <i>R. Herold (London, United Kingdom)</i>	11
08:20	The Pediatric Preclinical Testing Program (PPTP): changing the paradigm for drug development <i>P. Houghton (Memphis, USA)</i>	12
08:40	KidsCancerKinome: a EU-FP6 project for preclinical kinase inhibitor evaluation as a tool to prioritize compounds for paediatric development <i>H. Caron (Amsterdam, The Netherlands)</i>	13
09:00	Early phase drug development in the Children’s Oncology Group <i>P.C. Adamson (Philadelphia, USA)</i>	14
09:20	Early drug development in the childrens’ clinics in Europe <i>G. Vassal (France)</i>	15
Workshop 3		Room C
		Abstract number
08:00–09:45	Pharmacogenomics – where are we now? Chairs: W.D. Figg (Bethesda, USA) and R.E. Parchment (Frederick, MD, USA)	
08:00	Pharmacogenomics of anticancer drug disposition: we aren’t there yet <i>A. Sparreboom (Memphis, USA)</i>	16
08:25	Bioinformatics – from the bench to the bedside and back <i>G. Rajagopal (New Brunswick, USA)</i>	17
08:50	Pharmacogenomics in colon cancer: Fantasy or Reality <i>H. Lenz (Los Angeles, USA)</i>	18

09:15 High throughput genotyping and its possible applications in pharmacoepidemiology 19
D.G. Cox (Lyon, France)

Workshop 4**Room A**

Abstract number

10:15–12:00 **Phase 0 trials – are they necessary?**
 Chairs: E. Leo (Beerse, Belgium) and J. Doroshov (Bethesda, USA)

10:20 Phase 0 microdosing studies as part of the learn/confirm approach to drug development 20
C. Garner (Heslington York, United Kingdom)

10:45 Use of phase 0-changes in cancer drug development 21
J. Collins (Rockville, USA)

11:10 Implementation of phase 0 trials 22
J.H.M. Schellens (Amsterdam, The Netherlands)

11:35 Industry perspective 23
G. Gordon (USA)

Workshop 5**Room B**

Abstract number

10:15–12:00 **Targeting the CYP pathway**
 Chairs: A.M. Burger (Detroit, MI, USA) and G. Demetri (Boston, USA)

10:15 The evolution of CYPs from metabolising enzymes to potential targets in cancer therapy 24
 development
L.H. Patterson (Bradford, United Kingdom)

10:40 CYP-activated prodrugs as chemotherapeutics 25
R. Plummer (Newcastle upon Tyne, United Kingdom)

11:05 Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate 26
 cancer (CRPC): the Royal Marsden Hospital experience
A. Reid (London, United Kingdom)

11:30 Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/CYP26 inhibitors 27
 for breast cancer therapy
V.C.O. Njar (Baltimore, USA)

Workshop 6**Room C**

Abstract number

10:15–12:00 **Design and conduct of phase II trials for targeted agents**
 Chairs: J.A. Zwiebel (Rockville, USA) and G. Pond (Ontario, Canada)

10:15 Adaptive phase II trials 28
D. Berry (USA)

10:40 Parallel phase II trials – European perspective 29
D. Lacombe (Brussels, Belgium)

11:05 Patient enrichment strategy in phase II 30
J. De Bono (United Kingdom)

11:30 Using biomarkers in phase II studies 31
J. Tabernero (Barcelona, Spain)

Keynote Lecture**Room ABC**

Chair: P. Schöffski (Leuven, Belgium)

Abstract number

14:00–15:00 New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 32
E. Eisenhauer (Kingston, Canada)

Plenary session 2**Room ABC**

Abstract number

15:00–16:00 Proffered paper session

Chairs: L.J. Helman (Bethesda, USA) and J.C. Soria (Villejuif, France)

15:00 Preclinical evaluation of ⁶⁴Cu labeled bevacizumab by PET/CT imaging in tumor models 33
Z. Wang (Mattawan, USA)

15:15 Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263 34
Y. Chiu (Abbott Park, USA)

15:30 Clinical attrition rates for kinase inhibitors in oncology 35
I. Walker (London, United Kingdom)

15:45 A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours 36
P. Schöffski (Leuven, Belgium)

Plenary session 3**Room ABC**

Abstract number

16:30–18:15 Molecular targets – state of the science B

Chairs: P. Ivy (Rockville, USA) and A. Awada (Brussels, Belgium)

16:30 Drugging the cancer chaperone Hsp90: From chemical biology with natural products to active drugs in the clinic 37
P. Workman (Sutton, United Kingdom)

16:55 Bortezomib therapy of multiple myeloma 38
K. Anderson (Boston, USA)

17:20 Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer 39
K. Sakamoto (Los Angeles, USA)

17:45 Role of autophagy in cancer and therapy 40
E. White (Piscataway, USA)

Poster Sessions**Angiogenesis**

Abstract number

DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B 41
N.J. Serkova, J. Spratlin, S.G. Eckhardt, B. Milestone, E.G. Chiorean, H. Youssoufian, F. Fox, E. Rowinsky, R.B. Cohen

NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort 42
M. Mita, M.A. Spear, L.K. Yee, K.P. Papadopoulos, E.I. Heath, M. Pilat, O. Romero, G.K. Lloyd, A. Mita, P. LoRusso

Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC) <i>T. Okusaka, F. Kanai, M. Ikeda, C. Morizane, H. Yoshida, R. Tateishi, S. Shiina, Y. Kondo, K. Tagawa, M. Omata</i>	43
The BH4 domain is required for proangiogenic function of bcl-2 <i>D. Del Bufalo, D. Trisciuglio, M. Desideri, S. Scarpino, L. Ruco, G. Zupi</i>	44
VEGF targeting increases the cystostatic effect of docetaxel on prostate and breast tumor cells; a new interpretation of the therapeutic effect <i>G. Pagès, J. Durivault, J.M. Hannoun-Levi, A. Viera, C. Ortholan</i>	45
VEGF receptor expression in human tumours: VEGFR-2 and -3 are confined predominantly to tumour vasculature <i>N.R. Smith, D.J. Baker, N.H. James, K.E. Ratcliffe, S.E. Ashton, N. Gray, A.J. Ryan, J.M. Jürgensmeier, C. Womack</i>	46
UNBS5162: A new naphthalimide derivative with radiosensitizing and anti-angiogenic activity entering phase I <i>T. Mijatovic, N. De Nève, C. Bruyère, G. Simon, J. Dewelle, E. Van Quaquebeke, E. Van Der Aar, F. Van Vynckt, F. Lefranc, R. Kiss</i>	47
sFLT01, an anti-angiogenic protein with antitumor activity <i>R. Bagley, M. Yao, L. Kurtzberg, H. Rubin, W. Weber, P. Pechan, W. Brondyk, A. Scaria, J. Kaplan, B. Teicher</i>	48
Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI) <i>J. Spratlin, H.T. Arkenau, S. George, N.J. Serkova, M. Germuska, K. Brock, R. Gedrich, M. Scurr, G.D. Demetri, D.R. Camidge</i>	49
Unique enzymatic profile of a potent and selective VEGFR/PDGFR tyrosine kinase inhibitor, TAK-593: potent pseudo-irreversibility against VEGFR and PDGFR <i>H. Miki, H. Iwata, M. Amamo, S. Imamura, Y. Takagi, A. Hori</i>	50
TAK-593, a potent and selective VEGFR/PDGFR tyrosine kinase inhibitor, effects the tumor vascularity and vascular permeability <i>A. Hori, Y. Kakoi, Y. Takagi, K. Nakamura, S. Tsuchiya</i>	51
VEGFR2 targeted antibody and small molecule combinations in renal cell and hepatocellular cancer models <i>J.R. Tonra, E. Corcoran, I. Duignan, M.J. Plym, J. Schwartz, H. Youssoufian, D. Surguladze, Z. Zhu</i>	52
Combination treatment of VEGFR inhibitor AV-951 and rapamycin reveals distinct mechanisms of each agent's anti-tumor activity <i>M. Robinson, J. Lin, H. Yang, X. Sun, V. Ona, K. Kannan, J. Heyer, G. Meng, Y. Zhou, W. Rideout</i>	53
Common usage of the GEP100-Arf6-AMAP1 pathway in tumor invasion, angiogenesis and vascular permeability <i>A. Hashimoto, S. Hashimoto, E. Ogawa, M. Hirose, M. Morishige, T. Menju, M. Shibuya, H. Sabe</i>	54
Combination therapy of an anti-PDGFR β antibody with an anti-VEGFR2 antibody leads to enhanced antitumor activity <i>J. Shen, M. Prewett, C. Damoci, H. Zhang, M.D. Vil, H. Li, J. Tonra, Z. Zhu</i>	55
In vivo profiles of a novel compound, TAK-593, a highly potent and selective inhibitor against VEGFR and PDGFR tyrosine kinases <i>A. Mizutani, Y. Nagase, K. Nakamura, A. Hori</i>	56
Calixarene-based angiogenesis inhibitor 0118 attenuates endothelial cell energy and promotes a cytotoxic T-cell-mediated anti-tumor response <i>K. Mayo, R.P.M. Dings, K.B. Vang, A.W. Griffioen, M. Farrar</i>	57
Novel approaches to breast cancer therapy – simultaneous targeting to tumor and endothelial cells of tumor blood vessels <i>V. Moura, M.C.P. Lima, S. Simões, J.N. Moreira</i>	58
Antiangiogenic and tumor growth inhibitory effects of heparin-taurocholate conjugate <i>Y. Byun, S.Y. Kim, R.W. Park, E.S. Lee</i>	59

Expression of a gastrin transcript in gastrointestinal cancer cells which allows maintenance of expression in hypoxia <i>A. Grabowska, C. Berry, M. Bushell, A. Willis, S.A. Watson</i>	60
Contrast enhanced perfusion CT (CEPCT) predicts early response of sunitinib in renal cell carcinoma (RCC) patients <i>V. Grünwald, N. Hastuerk, M. Fenner, P. Ivanyi, C. Reuter, A. Ganser, M. Galanski, H. Shin</i>	61
Expression and functional activity of interleukin-8 receptors on human malignant melanoma cells <i>D. Trisciuglio, C. Gabellini, G. Zupi, D. Del Bufalo</i>	62
Response of papillary cell carcinoma to antiangiogenics: a retrospective analysis <i>J. Medioni, J. Wassermann, V. Molinie, A. Vieillefond, A. Cassar, A. Meajeau, S. Oudard</i>	63

Animal models

Abstract number

Neurobehavioral properties of penclomedine (PEN) and derivatives <i>L.R. Morgan, M.E. Thornton, E.N. Benes, R.F. Struck, A.H. Rodgers, B.S. Jursic, G.J. LaHoste, G. Bastian, R.B. Thompson</i>	64
Hypoxic conditions increase hypoxia response element and vascular endothelial growth factor promoter reporter activity within the hollow fibre assay in vivo <i>R. Argent, Y. Yin, A.M. Grabowska, P. Clarke, N. Mann, E. Royal, S.A. Watson</i>	65
Synergistic anti tumor effect of histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of malignant melanoma <i>Y. Kato, I. Yoshino, T. Maeda, R. Tsuboi</i>	66
A relevant panel of human uveal melanoma xenografts directly established from primary and/or metastatic patient's tumor for pharmacological preclinical assays <i>F. Némati, X. Sastre, J. Couturier, P. Mariani, S. Piperno-Neumann, L. Desjardins, O. Lantz, A. Dahiani, S. Arrufat, M.F. Poupon, D. Decaudin</i>	67
Sensitivity of a disseminated in vivo model of L363 plasma cell leukaemia against antitumoral compounds sorafenib, bortezomib, and dexamethasone <i>J. Schueler, D. Wider, M. Wagner, H.H. Fiebig, M. Engelhardt</i>	68
Evaluating the dual kinase inhibitor lapatinib: Bioanalytical method development and pharmacokinetic analysis in mouse, rat, and human and determination of in vivo efficacy in a panel of EGFR wildtype and mutant human tumor xenograft models <i>J. Cooper, F.E. Nieves, J. Kuhn, C.H. Takimoto, A.W. Tolcher, M.J. Wick</i>	69
In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response <i>M. Batey, J.L.R. Brito, H. Maitland, H. Leung, A. Hall, G. Jackson, D.R. Newell, J.A.E. Irving</i>	70
Features of chemo and radiotherapy response of a new model of breast cancer xenograft derived from a BRCA2 germ-line mutation carrier patient's tumour <i>E. Marangoni, L. De Plater, B. Froget, L. Durand, S. Piperno-Neumann, B. Sigal-Zafrani, D. Stoppa-Lyonnet, A. Laugé, D. Decaudin, M.F. Poupon</i>	71
Preclinical evaluation of the tyrosine kinase inhibitor erlotinib: Bioanalytical method development and pharmacokinetic analysis and in vivo evaluation and comparison in a panel of human EGFR wildtype and mutant tumor xenograft models <i>F.E. Nieves, J. Cooper, G.L. Mangold, J. Kuhn, C.H. Takimoto, A.W. Tolcher, M.J. Wick</i>	72
Establishment of human primary tumor xenograft models in nude mice <i>C. Liu, Y. Liu, W. Pan, Y. Chen</i>	73
Experimental therapeutic approach of human diffuse large B-cell lymphoma xenografts by doxycycline, alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab <i>F. Assayag, N. Brousse, J. Couturier, E. Macintyre, C. Mathiot, L. De Plater, S. Dewulf, A. Vincent-Salomon, M.F. Poupon, D. Decaudin</i>	74
Establishment, validation, and in vivo evaluation of tumor explant models of adenoid cystic carcinoma: effects of FDA-approved and candidate therapies in human ACC xenografts <i>F.E. Nieves, C.A. Moskaluk, D. Sidransky, C.H. Takimoto, A.W. Tolcher, J. Kaufman, M.J. Wick</i>	75
Imaging the totality of cancer progression in real time <i>R. Hoffman</i>	76

Biomarkers	Abstract number
Prediction and in vivo validation of AZD0530 sensitivity by gene expression profiling in human pancreatic tumor xenografts <i>N.V. Rajeshkumar, A.C. Tan, J. Wheelhouse, A. Jimeno, W.A. Messersmith, T.P. Green, M. Hidalgo</i>	77
Tyrosine kinase inhibitors, such as TAK-285, GW572016 or SU11248, protect or damage the heart based on their ability to activate AMPK <i>S.A. Shell, R.L. Wappel, P. Trusk, Y. Ohta, W. Klohs, S.S. Bacus</i>	78
Development of a gene signature predicting response to Cetuximab in human tumor xenograft models <i>H. Fiebig, J.B. Schüler, T. Metz, T. Beckers, A. Korrat</i>	79
Inhibition of MEK1/2 signalling results in decreased levels of intracellular lactate in human melanoma and colorectal cancer cells as observed with magnetic resonance spectroscopy <i>M. Falck Miniotis, P. Workman, M.O. Leach, M. Belouche-Babari</i>	80
Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multitargeted kinase inhibitor in Phase I clinical trials <i>N. Beaulieu, I. Dupont, C. Beaulieu, H. Nguyen, H. Ste-Croix, S. Claridge, L. Isakovic, A. Vaisburg, J.M. Besterman, C. Maroun</i>	81
Prevalence of G12R or Q61H K-Ras mutations in pancreas cancer and development of Ras-targeted immunotherapy <i>A. Franzusoff, Z. Guo, Y. Lu, S. Oakes, A. Britton, V. Fiolkoski, T. King, D. Quick, J. Frenz, D. Apelian</i>	82
A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor <i>V. Novotny-Diermayr, V.M. Nayagam, H.H. Hentze, A.L. Liang, Y.K. Loh, N. Sausgruber, P. Yeo, K. Ethirajulu, J.M. Wood</i>	83
Development of predictive markers of responsiveness to the MEK 1/2 Inhibitor AZD6244 in Colorectal Cancer (CRC) <i>S. Nallapareddy, J.J. Tentler, C.D. Coldren, T.M. Pitts, S.A. Kaufman, S.G. Eckhardt</i>	84
Pharmacodynamic and efficacy relationship of MLN4924, a novel small molecule inhibitor of Nedd8-activating enzyme, in human xenograft tumors grown in immunocompromised mice <i>A. Berger, J. Yu, J. Garnsey, M. Milhollen, J. Zhang, T. Traore, L. Tou, A. McDonald, K. Burke, P.G. Smith</i>	85
Aberrant promoter hypermethylation of DAPK gene is an independent prognostic factor in patients with diffuse large B-cell lymphomas <i>K. Amara, M. Trimeche, S. Ziadi, L. Laatiri, M. Hachana, S. Korbi</i>	86
Correlation analysis utilizing measurements of tumor biomarkers and antibody efficacy against EGFR, IGF1R and VEGFR2 receptors in multiple tumor models <i>D. Deevi, L. Huling, D.L. Ludwig, Z. Zhenping, L. Witte, J. Tonra</i>	87
Development of proximity-based immunoassays for activated HER1, HER2, and HER1-HER2 heterodimers in formalin-fixed, paraffin-embedded (FPPE) cells <i>L. Defazio-Eli, J. Wallweber, K. Frankson, T. Dao-Pick, T. Dang, R. Dua, L. Goodman, G. Parry, J. Winslow</i>	88
Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway <i>A.D. Laird, A. Sillman, B. Sun, A. Mengistab, F. Chu, M. Lee, B. Cancilla, S.K. Aggarwal, F. Bentzien</i>	89
Differential effects of blockade of the HER3-PI3K-Akt pathway by EGFR kinase inhibitors and EGFR monoclonal antibodies on combinations with IGF-1R kinase inhibition <i>E. Buck, A. Eyzaguirre, D. Epstein, J. Pachter, J. Haley, N. Miglarese, K. Iwata</i>	90
Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC) <i>T.M. Pitts, S.A. Kaufman, J.J. Tentler, S. Leong, C.D. Coldren, F.R. Hirsch, M. Varella-Garcia, S.G. Eckhardt</i>	91

Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition	92
<i>B. Jacobs, R. Van Oirbeek, B. Biesmans, S. Fieuws, W. De Roock, J. De Schutter, Y. Humblet, M. Peeters, E. Van Cutsem, S. Tejpar</i>	
Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase	93
<i>A. Chakravarty, V.B. Shinde, K. Galvin, L. Silverman, B. Stringer, H. Danaee, O. Eton, M. Manfredi, J. Ecsedy</i>	
Expression of leptin receptor is an independent prognostic marker of Middle Eastern colorectal carcinomas	94
<i>K. Al-Kuraya</i>	
A comparative analysis of megakaryocyte potentiating factor and mesothelin as serum markers for the detection of malignant pleural mesothelioma	95
<i>K. Iwahori, S. Serada, T. Takahashi, Y. Souma, M. Kim, Y. Kishi, I. Kawase, T. Naka</i>	
Potential importance of the ceramide pathway in the action of the tumour vascular disrupting agent ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid)	96
<i>B.C. Baguley, Q. Ding, P. Kestell, S. Alix</i>	
Analysis of EGFR and KRAS mutations in circulating tumor DNA (ctDNA) from plasma of NSCLC patients in phase 2 trials of XL647	97
<i>F. Schimmoller, N.A. Rizvi, V.S. Vysotskaia, R.P. Funke, S. Dixon, R.E. Buller</i>	
DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease	98
<i>W. De Roock, M. Janssens, B. Biesmans, B. Jacobs, J. De Schutter, Y. Humblet, M. Peeters, E. Van Cutsem, P. Marynen, S. Tejpar</i>	
Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation	99
<i>R. Wooster, W. Cornwell, J. Jing, J. Greshock, A. Gilmartin, D. Sutton, J. Jackson, S. Laquerre, B. Weber, Y. Degenhardt</i>	
The Expression of c-erb B2 and p53 in human gastric cancer: Correlation to clinicopathologic features and cancer recurrence	100
<i>H. Hur, W. Kim, H.M. Jeon</i>	
Identification of alpha-enolase autoantibody as a novel biomarker in non-small cell lung cancer	101
<i>S. Serada, P. He, T. Takahashi, K. Iwahori, Y. Souma, A. Kim, T. Naka</i>	
Quantitative clinical biomarker measurement using multiplexed quantum dot immunohistochemistry	102
<i>E. Sweeney, T.H. Ward, N. Gray, C. Womack, G. Jayson, A. Hughes, C. Dive, R. Byers</i>	
Development of highly quantitative, sensitive, and reproducible immunoassays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded (FFPE) tumor tissue	103
<i>Y. Shi, A. Mukherjee, J. Weston, J. Bose, X. Nguyen, A. Paquet, C. Chappey, G. Parry, L. Goodman</i>	
Role of P21 in sensitivity to DACH-platinum compounds, oxaliplatin and ProLindac, in human cancer cells	104
<i>M. Serova, I. Bieche, M. Broggini, E. Erba, A. Ghoul, M. D'Incalci, E. Cvitkovic, D. Nowotnik, S. Faivre, E. Raymond</i>	
Evaluation of PET tracer uptake in mouse xenograft models of hormone-dependent prostate cancer	105
<i>D. Kukuk, G. Reischl, O. Raguin, S. Wiehr, F. Cay, D. Bukala, O. Duchamp, J.M. Judenhofer, H.J. Machulla, B. Pichler</i>	
-765G>C COX2 polymorphism and bladder cancer onset: implications for chemoprevention in a Portuguese population	106
<i>A. Pereira, L. Lima, S. Magalhães, L. Santos, R. Medeiros</i>	
Novel epitopes presented by the HLA-A*0201 are recognized by the cytotoxic T lymphocytes of breast cancer survivors	107
<i>O. Hawkins, R. VanGundy, A. Eckerd, W. Bardet, R. Buchli, J. Weidanz, W. Hildebrand</i>	
Screening Plasma Thioredoxin-1 (Trx-1) to potentially guide clinical development of the Trx-1 Inhibitor PX-12	108
<i>D.L. Kirkpatrick, A. Hiscox, M. Boice, D. Swanlund, L. Baronic, L. Pestano</i>	
Promoter hypermethylation of the NORE1A occurs in endometrial cancer	109
<i>H. Chung, J. Kim, N. Park, Y. Song, S. Kang</i>	

TM9SF2, a novel cell surface potential target in breast cancer	110
<i>S. Abou-Sharieha, Y. Sugii, H. Tada, M. Seno</i>	
Design of a screening procedure to select patients with leukemia for treatment with F 14512, a novel targeted cytotoxic agent	111
<i>J.M. Barret, J.P. Annereau, V. Brel, M. Broussas, Y. Guminski, T. Imbert, C. Dumontet, L. Goetsch, N. Guilbaud, C. Bailly</i>	
A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis	112
<i>P. Moretto, S.J. Hotte, H.W. Hirte, A. Iacobucci, K. Evans, D. Wong, W. Korz, P.A. Kavsak</i>	

Chemoprevention

Abstract number

The RhoA kinase (ROCK) inhibitor Y27632 and specific novel structural analogues of this compound cause irreversible elimination of transformed NIH3T3 cells from cultures	113
<i>L. Hampson, X.T. He, A.W. Oliver, J. Hadfield, T. Kemp, A. McGown, J. Butler, H.C. Kitchener, I.N. Hampson</i>	
Ursodeoxycholic acid decreases proliferation of normal intestinal epithelial cells in vivo and in vitro	114
<i>S. Subramanian, C. Loddenkemper, M.L. Hanski, M. Zeitz, C. Hanski</i>	
Effects of MMR status on colon carcinoma cell survival after 5-FU treatment in vitro and in vivo	115
<i>B. Choudhary, M.L. Hanski, M. Bhonde, M. Zeitz, C. Hanski</i>	
Effective combination of green tea EGCG and EGFR-TKI erlotinib for chemoprevention and therapy in head and neck cancer	116
<i>D.M. Shin, A.R.M. Amin, X. Zhang, Z.G. Chen, F.R. Khuri</i>	

Drug delivery

Abstract number

ANG1005, Paclitaxel conjugated to the angiopep brain transport vector for the treatment of brain cancer: preclinical studies	117
<i>R. Gabathuler, M. Demeule, A. Regina, C. Che, F. Thomas, A. Abulrob, Q.R. Smith, D. Stanimirovic, R. Beliveau, J.P. Castaigne</i>	
Comparative pharmacokinetic study of abiraterone acetate in a capsule and tablet formulation	118
<i>F.I. Raynaud, V. Martins, T. Yap, C. Carden, R.L. Jones, S.B. Riggs, F.F. Kabbinar, D. McIntosh, G. Lee, J.S. De Bono</i>	
The effects of treatment sequencing on the antitumor activity of vandetanib and paclitaxel in a model of ovarian carcinoma xenograft	119
<i>M. Cesca, R. Frapolli, S. Scarlato, A.J. Ryan, E. Bello, R. Giavazzi</i>	
Customized PEG linkers improve tumor delivery of RNA antagonist oligonucleotides	120
<i>H. Zhao, P. Sapra, P. Reddy, R. Bandaru, M. Wang, P. Zhu, M. Mehlig, P. Kraft, L.M. Greenberger, I.D. Horak</i>	
Novel customized releasable polyethylene glycol (PEG) linkers improve tumor delivery and efficacy of locked nucleic acids oligonucleotides	121
<i>P. Sapra, H. Zhao, P. Reddy, M. Wang, R. Bhandaru, J. Malaby, P. Kraft, M. Mehlig, L.M. Greenberger, I.D. Horak</i>	
In silico modelling of doxorubicin penetration through multicell layers	122
<i>R. Phillips, P. Loadman, P. Jones, S. Smye, C. Twelves, B. Sleeman, C. Evans</i>	
Potent synergy of dual anti-tumor peptides for growth suppression of human glioblastomas using highly efficient peptide-delivery system	123
<i>E. Kondo, T. Yoshino</i>	
Nanoparticles as drug delivery device in cancer therapy: investigation of nanodiamond internalization and cellular effects in endothelial and glioblastoma cells	124
<i>A. Pagano, S. Honoré, V. Joshi, A. Barbier, M. Sennour, A. Thorel, A. Krueger, P. Curmi, D. Braguer</i>	
The antineoplastic activities of a novel oral formulation of interleukin-2 (IL-2)	125
<i>S. Ko, S. Zhang, R. Qu, X. Chen, M. Sullivan</i>	
Novel phage display-derived peptides for tumor- and vascular-targeted therapies against neuroblastoma	126
<i>F. Pastorino, S. Marchiò, D. Di Paolo, M. Loi, A. Corti, F. Bussolino, D. Ribatti, W. Arap, R. Pasqualini, M. Ponzoni</i>	

Drug screening	Abstract number
Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK) <i>C. Cano, N.J. Curtin, B.T. Golding, K. Haggerty, I.R. Hardcastle, M. Hummersone, K. Menear, C. Richardson, G.C.M. Smith, R.J. Griffin</i>	127
Unraveling therapeutic bio-signatures through pathway mapping at the single cell level using an analysis platform for simplified interrogation of complex data sets <i>A. Cappione, L. Zieske, R. Lefebvre, D. King</i>	128
Design, synthesis and evaluation of bivalent conformationally constrained Smac mimetics as a new class of anticancer agents <i>H. Sun, J. Lu, L. Bai, Z. Nikolovska-Coleska, C. Yang, S. Qiu, X. Ling, M. Guo, D. Yang, S. Wang</i>	129
Structure–activity relationships for a library of C2-aryl substituted monomeric pyrrolo[2,1-c][1,4]benzodiazepines (PBD) antitumour agents <i>M. Coffils, D.I. Jodrell, S.M. Guichard, J.A. Hartley, P.W. Howard, D. Antonow, D.E. Thurston</i>	130
Specific induction of the p53 pathways by low dose cytotoxic drugs assessed by gene expression pattern analysis <i>M.L. Choong, P.Z.K. Kwek, H. Yang, M.A. Lee, D.P. Lane</i>	131
SRJ09, a lead compound in anticancer drug design: in vitro, in vivo and mechanistic studies <i>J. Stanslas, S.H. Lim, S.R. Jada, S.R. Sagineedu, N.H. Lajis, M.F. Stevens</i>	132
Discovery of potent and selective focal adhesion kinase inhibitors <i>E. Kawahara, T. Miyake, N. Matsuura, I. Umemura, K. Masuya, T. Kanazawa, T. Meyer, J. Mestan, S. Hatakeyama, O. Ohmori</i>	133
The rational design of inhibitors of the telomere-hnRNP A1 interaction <i>X. Billot, R. Marcellus, L. Belec, J.F. Trempe, N. Safaee, K. Gehring, J. Schrag, M. Cygler, M. Lawless, P. Beauparlant</i>	134
Design and synthesis of BCA2 inhibitors <i>G. Brahemi, A. Fiasella, A. Brancale, A. Westwell, A. Burger</i>	135
Discovery of SB939, an HDAC inhibitor with a superior preclinical profile <i>H. Wang, N. Yu, D. Chen, E.T. Sun, K. Sangthongpitag, Z. Bonday, P. Yeo, E. Kantharaj, J.M. Wood, B.W. Dymock</i>	136
Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2 <i>S. Erskine, C. Rominger, F. Zappacosta, S. Laquerre, J. Adams, P. Tummino, Z. Lai</i>	137
Design, synthesis, biochemical and biological evaluations of novel and potent small-molecule inhibitors of STAT3 <i>J. Chen, L. Bai, Z. Nikolovska-Coleska, J. Zhang, C. Gomez, H. Yi, K. Krajewski, S. Jiang, P. Roller, S. Wang</i>	138
Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate <i>F. Bichat, M. Demeule, B. Lawrence, O. Raguin, B. Sourzat, R. Gabathuler, J.P. Castaigne, P. Genne</i>	139
Macrolactone based inhibitors of Heat Shock Protein 90 <i>J.E.H. Day, C.J.M. Moody, P. Workman</i>	140
Design and synthesis of novel indole derivatives as selective apoptosis-inducers <i>N.I. Ziedan, A.D. Westwell, S. Fogli</i>	141
Interaction of chlorambucil and intercalating aniline mustards with defined DNA sequences using MALDI and ESI mass spectrometry <i>A.M.S. Abdul Majid, G. Smythe, W.A. Denny, L.P.G. Wakelin</i>	142
Ex-vivo plasma protein binding and in vitro evaluation of AP5346 (ProLindac TM; PL), a novel polymer-bound platinum: Evidence showing that >72 h DACH-platinum (Pt) release may play a major role in cytotoxicity <i>K. Rezai, M. Serova, E. Raymond, S. Faivre, F. Bourdel, E. Cvitkovic, S. Weill, S. Urien, F. Lokiec</i>	143
Heat shock proteins	Abstract number
XL888, a novel, synthetic, orally bioavailable inhibitor of Hsp90 <i>M. Nicoll</i>	144
Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer <i>P.A. Clarke, L. Welsh, M. Valenti, S. Eccles, P. Workman</i>	145

CU-0305, a novel synthetic Hsp90 inhibitor with unique pharmacology properties	146
<i>R. Boa, C. Lai, H. Qu, D. Wang, L. Yin, X. Cai, H. Zhai, G. Xu, X. Tao, B. Zifcak, C. Qian</i>	
AT13387, a fragment derived clinical candidate is active in lung and melanoma models	147
<i>J. Lyons, B. Graham, J. Curry, M. Reule, T. Smyth, L. Fazal, B. Williams, M. Yule, M. Squires, N. Thompson</i>	
Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors	148
<i>C. Fritz, B. Tillotson, J. Ge, E. Normant, K. Depew, J. Basuki, N. Hafëez, J. Patterson, J.R. Porter, V. Palombella</i>	
Acetylation of molecular chaperones by histone deacetylase inhibitors (HDACI)	149
<i>K. Reynald, M. Rowlands, A. Hardcastle, L. Stimson, A. Bannister, P. Workman, W. Aherne</i>	
MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models	150
<i>D. Wettstein, V. Baichwal, D. Papac, D. Cimborá, R. McKinnon, A. Bajji, S.H. Kim, R. Tangallapally, B. Markovitz, R. Trovato</i>	
Efficacy of panobinostat (LBH589) in lung cancer: potent anticancer activity in both in vitro and in vivo tumor models	151
<i>P. Atadja, W. Shao, Y. Wang, J. Gowney, Y. Feng, Y.M. Yao, A. Wallace, C. Crisanti, S. Fawell, S. Albelda</i>	
Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat	152
<i>Z. Zhong, J. Simmons, P. Timmermans</i>	
IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class	153
<i>J. Lee, L. Grenier, E. Holson, K. Slocum, J. Ge, E. Normant, J. Hoyt, J. Cushing, J. Sydor, J. Wright</i>	
Hsp90 is expressed and represents a novel target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin	154
<i>X. Wu, P. Wardega, L. Gedda, A. Wanders, S. Bergström, L. Sooman, J. Gullbo, M. Bergqvist, J. Lennartsson, S. Ekman</i>	
Pharmacokinetic/pharmacodynamic relationship in human xenograft models and PBMC's treated with the Hsp90 inhibitor NVP-AUY922	155
<i>M.R. Jensen, S. Ide, J. Brueggen, J. Schoepfer, M. Motwani, X. Wang, T. Radimerski, C. Quadt, C. Garcia-Echeverria, P. Chene</i>	
BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with standard of care therapies in preclinical tumor models	156
<i>K. Lundgren, N. Timple, G. Ibanez, C. Yang, L. Neely, A. Kamal, K. Hong, H. Zhang</i>	

Hormonal agents

Abstract number

BMS-641988: A highly potent and rationally designed inhibitor of the androgen receptor (AR), with efficacy in castration resistant human prostate cancer xenograft models	157
<i>M. Salvati, R.M. Attar, A. Balog, J. Dell-John, M. Jure-Kunkel, S. Krystek, M. Obermeier, T.J.R. Spires, G. Vite, M. Gottardis</i>	
Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy-naïve and docetaxel treated castration-resistant prostate cancer (CRPC)	158
<i>G. Attard, A. Reid, N. Babu Oommen, L. Folkerd, D. Olmos, E. Thompson, G. Maier, M. Dowsett, D. Dearnaley, J.S. De Bono</i>	
Re-inducing sensitivity to abiraterone acetate, a novel CYP17 inhibitor with a high level of anti-tumour activity in castration resistant prostate cancer	159
<i>N. Oommen, G. Attard, A. Reid, L. Folkerd, P. Fong, J. Hunt, M. Dowsett, D. Dearnaley, C. Parker, J. De-Bono</i>	
Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium	160
<i>H. Scher, T. Beer, C. Higano, C. Logothetis, J. Shelkey, D. Hung, M. Hirmand, S. Larson, M. Fleisher, C. Sawyers</i>	

Potent anticancer activity of panobinostat (LBH589) in models of hormone-refractory prostate cancer (HRPC): targeting the androgen receptor <i>W. Shao, J. Growney, G. O'Connor, Y. Feng, H. Scher, Y.M. Yao, S. Fawell, P. Atadja</i>	161
Effects of SOD2 silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer <i>N. Sharifi, E.M. Hurt, S. Thomas, W.L. Farrar</i>	162
The steroid sulfatase inhibitor BN83495 inhibits E1S-stimulated growth of DMBA-induced mammary tumour in rat <i>Z. Koob, M. Hillairet de Boisferon, F. Bichat, E. Bascompta, A. Perez, B. Potter, M. Reed, T. Ali, G.P. Prevost</i>	163

Metastasis and invasion Abstract number

Inhibition of CXCR-4 reduces breast cancer xenograft metastasis to multiple organs <i>M.M. Richert, D. Wong, W. Korz, D.R. Welch</i>	164
Novel therapeutic efficacy of E7080 for controlling experimental metastases of human lung cancer cells in natural killer cell-depleted severe combined immunodeficient mice <i>M. Hanibuchi, H. Ogino, K. Ikuta, S. Kakiuchi, H. Uehara, A. Tsuruoka, T. Uenaka, Y. Nishioka, S. Yano, S. Sone</i>	165
Inhibitors of mitochondrial ATP synthesis show preferential cytotoxicity to pancreatic cancer cells under glucose-deprived conditions <i>I. Momose, D. Tatsuda, M. Kawada, D. Ikeda</i>	166
The EGFR-GEP100-Arf6 pathway in breast cancer invasion and metastasis <i>S. Hashimoto, M. Morishige, E. Ogawa, Y. Toda, H. Kotani, M. Hirose, A. Hashimoto, Y. Nio, H. Wada, H. Sabe</i>	167
Endothelin A receptor/beta-arrestin signaling is critical for ovarian cancer metastasis: novel molecular therapeutic applications <i>L. Rosanò, R. Cianfrocca, S. Masi, F. Spinella, V. Di Castro, A. Biroccio, E. Salvati, R. Nicotra, P.G. Natali, A. Bagnato</i>	168
PI3K/Akt pathway regulates Shh/Gli-mediated EMT and invasion of gastric cancer cells <i>M.H. Kang, H.N. Kang, J.L. Kim, J.S. Kim, Y.A. Yoo, S.C. Oh</i>	169
PI3K/Akt pathway regulates BMP2-mediated EMT and invasion of gastric cancer cells <i>J.L. Kim, M.H. Kang, H.N. Kang, J.S. Kim, S.C. Oh, Y.A. Yoo</i>	170
Integrin LFA-1 expression regulates angiogenesis-stimulating potential of colorectal carcinoma cells at premetastatic niches in the liver <i>M. Valcárcel, A. Jaureguibeitia, C. Salado, A. Lopategi, B. Arteta, F. Muruzabal, L. Mendoza, F. Vidal-Vanaclocha</i>	171
Tumor-induced liver nerve growth factor (NGF): a new target for stromal cell inhibition during metastatic colorectal carcinoma growth <i>F. Basaldua, A. Lopategi, B. Arteta, A. Valdivieso, J. Ortiz de Urbina, F. Vidal-Vanaclocha</i>	172
Arf6-AMAP1 pathway in invasion of lung cancer and malignant mesothelioma cell lines <i>T. Menju, S. Hashimoto, A. Hashimoto, E. Ogawa, H. Wada, H. Date, H. Sabe</i>	173
Epigenetic changes of tumor suppressor genes and therapeutic implications in glioblastoma <i>L. Sooman, J. Gullbo, J. Lennartsson, S. Bergström, E. Blomquist, M. Bergqvist, S. Ekman</i>	174

Natural products and marine compounds Abstract number

Role of ERK activation in triptolide-induced apoptosis in MDA-MB-231 human breast cancer cells <i>B.J. Tan, G.N. Chiu</i>	175
Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors <i>P. Schöffski, V. Grünwald, G. Giaccone, R. Salazar, M. Majem, H. Dumez, E. Casado, B. de las Heras, J.P. Armand</i>	176
Antiproliferative effects of fluoro-chalcone derivatives in human melanoma A375 cells and peripheral blood mononuclear cells <i>K. Henmi, Y. Hiwatashi, N. Toyama, T. Hirano</i>	177

Eph receptor A2 modulation in human glioma cell lines by the natural product, Schweinfurthin A <i>A. Monks, T. Turbyville, E.D. Harris, B. Kaas, J.A. Beutler</i>	178
Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma <i>J.C. Soria, R. Plummer, A. Soto, C. Massard, H. Calvert, R. Prados, E. Angevin, C. Jones, B. de las Heras</i>	179
The novel taxane derivative, IDN6140, crosses the Blood Brain Barrier and has a promising activity in CNS tumors <i>E. Marangon, F. Sala, R. Frapolli, C. Manzotti, P. Morazzoni, G. Pratesi, G. Petrangolini, M. Tortoreto, M. D'Incalci, M. Zucchetti</i>	180
Evaluation of the marine compound PM02734 against a pediatric tumor cell line panel by ITCC preclinical drug evaluation program <i>B. Geoerger, C. Lanvers, A. Verschuur, P. Aviles, C. Cuevas, J. Boos, G. Vassal, H. Caron</i>	181
In vitro and in vivo antitumor activity of novel aureolic acid analogues generated by metabolic engineering of the biosynthetic pathways in <i>Streptomyces argillaceus</i> and <i>Streptomyces griseus</i> subsp. <i>griseus</i> <i>A. Malek, L.E. Núñez, N. Menéndez, F. Moris, G.M. Carbone, J. Rohr, C. Méndez, J.A. Salas, C.V. Catapano</i>	182
New clerodane diterpenes from <i>Casearia capitellata</i> as potential antitumour agents <i>J. Stanslas, G. Bagalkotkar, S.C. Tang, A.S. Hamzah, K. Shaari, N.H. Lajis, M.S. Saad</i>	183
New antitumour agents from <i>Phyllanthus pulcher</i> , a tropical medicinal plant <i>J. Stanslas, G. Bagalkotkar, S.C. Tang, A.S. Hamzah, K. Shaari, N.H. Lajis, M.S. Saad</i>	184
Chlamydocin, a HDAC inhibitor identified by Compare analyses in a cellular screen <i>H.H. Fiebig, T. Metz, T. Beckers, A. Korrat, G. Kelter</i>	185
Screening for the inhibitor against filopodia protrusion <i>M. Kitagawa, E. Tashiro, T. Soga, M. Imoto</i>	186
Fusicoccin derivative (ISIR-005) suppresses anchorage-independent growth of cancer cells through anoikis activation <i>Y. Honma, M. Akimoto, T. Sassa, N. Kato</i>	187
Leucinoastatins suppress prostate cancer cell growth through the tumour-stromal cell interactions <i>M. Kawada, H. Inoue, I. Momose, T. Masuda, D. Ikeda</i>	188
Solution structure of a 2:1 C2-(2-naphthyl)pyrrolo[2,1-c][1,4]benzodiazepine (PBD) DNA adduct: molecular basis for unexpectedly high DNA helix stabilization <i>D. Antonow, T. Barata, T.C. Jenkins, G.N. Parkinson, P.W. Howard, M. Zloh, D.E. Thurston</i>	189

Paediatric – early drug development

Abstract number

Pediatric Preclinical Testing Program (PPTP) evaluation of rapamycin combined with cytotoxic drugs used frequently in treatment of childhood cancer <i>P.J. Houghton, C.L. Morton, J.M. Maris, S.T. Keir, R.B. Lock, H. Carol, R. Gorlick, E.A. Kolb, M.H. Kang, M.A. Smith</i>	190
Pediatric Preclinical Testing Program (PPTP) evaluation of the oncolytic picornavirus, NTX-010 (SVV-001) <i>C.L. Morton, P.J. Houghton, J.M. Maris, R. Gorlick, E.A. Kolb, M.H. Kang, C.P. Reynolds, M.A. Smith</i>	191
Pediatric Preclinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419 <i>R. Lock, H. Carol, P. Houghton, C. Morton, D. Phelps, C. Tucker, D. Payne-Turner, C. Zuany-Amorim, M. Smith</i>	192
Preclinical evaluation of the marine compound PM00104 within the ITCC pediatric tumor cell line panel in vitro and in vivo <i>A. Verschuur, C. Lanvers, B. Geoerger, P. Aviles, P. Rodier, C. Cuevas, J. Boos, G. Vassal, H. Caron</i>	193

Pharmacogenomics

Abstract number

How to prescribe standard chemotherapy or targeted-therapy using a fully featured relational database <i>E. Banu</i>	194
---	-----

Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies <i>A. Rinaldi, I. Kwee, F. Bertoni, L. Viganò, D. Hess, N. Coceani, C. Sessa, V.M. Rivera, C.L. Bedrosian, C.V. Catapano</i>	195
Intron 1 CA repeat polymorphism is associated with the sensitivity to EGFR TKIs in NSCLC patients with wild type EGFR <i>J.Y. Shin, J.O. Kim, S.J. Lim, H.S. Won, T.H. Kim, C.H. Lee, M.S. Kim, J.H. Kang</i>	196
Pathway determinants of 5-fluorouracil activity <i>W.L. Tan, D.F. Dong, L.S. Wong, R.A. Soo, I. Fichtner, R. Soong</i>	197
Genetic polymorphisms associated with adverse events in childhood acute lymphoblastic leukaemia treated with SHOP-2005 protocol <i>E. Lopez, I. Martin-Guerrero, J. Ballesteros, M.A. Piñán, A. Navajas, A. Garcia-Orad</i>	198
Influence of PXR haplotype variants on paclitaxel pharmacokinetics and pharmacodynamics in Asian cancer patients <i>B. Chowbay, E. Sandanaraj, S. Lal, Z.P. Wang, T. Kulkarni, W.T. Lim, C.S. Ang Peter, E.H. Tan</i>	199
Transcriptome analysis method for in vivo mechanism of action study: IMC-D11 anti-FGFR3 +/- cisplatin in bladder cancer models <i>W. Wang, Y. Cheng, D. Deevi, H. Li, M. Prewett, R. Bassi, M. Malabunga, K. Paz, H. Sun, J. Tonra</i>	200
In Mdm2 SNP309 cancer cells the small molecules nutlin-3 and MI-63 facilitate recruitment of RNA polymerase II to p53 target genes <i>J. Bargonetti, A. Polotskaia, S. Wang</i>	201
Predicting a metastatic treatment response in advanced colorectal cancer patients by gene expression profiling <i>M. Del Rio, C. Bascoul-Mollevi, F. Bibeau, P. Chalbos, A. Kramar, C. Gongora, M. Ychou, P. Martineau</i>	202

Phase II

Abstract number

Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer <i>B. Besse, K.D. Eaton, J.C. Soria, T.J. Lynch, V. Miller, K.K. Wong, C. Powell, S. Quinn, C. Zacharchuk, L.V. Sequist</i>	203
Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study <i>T.W. Flaig, B.D. Curti, M.S. Gordon, P.J. Van Veldhuizen, W.H. Miller, M.S. Ernstoff, S. Bhatia, N.H. Hunder, N. Royer, J.A. Thompson</i>	204
A phase II study of oral enzastaurin HCl in patients with metastatic colorectal cancer <i>B. Glimelius, M. Lahn, S. Gawande, L. Musib, Y. Liu, K.L. Spindler, C. Qvortrup, P. Pfeiffer, A. Jakobsen</i>	205
Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC) <i>S.J. Hotte, E.X. Chen, H.W. Hirte, P. Moretto, S. Turner, S.F. Chin, L. Wang, K. MacAlpine, L.L. Siu</i>	206
Phase II study of gefitinib in combination with cisplatin and concurrent radiotherapy in patients with stage III/IV squamous cell head and neck cancer and to analyse the effect of gefitinib on tumour gene expression <i>E.H. Tan, C. Goh, A. Loy, S.S. Leong, W.T. Lim, C.K. Toh, T. Tan, J. Wee, K.W. Fong, K.M. Hui</i>	207
A phase II study of sunitinib, an oral multi-targeted tyrosine kinase inhibitor, in patients with unresectable, locally advanced or metastatic cervical carcinoma: IND184 <i>H. Mackay, A. Tinker, E. Winquist, G. Thomas, J. Sederias, P. Ivy, E.A. Eisenhauer</i>	208
An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer <i>G. MacVicar, F.A. Greco, J. Reeves, B. Curti, B. Poiesz, B. Somer, K. Brill, L. Leopold</i>	209
Preliminary results of a Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing first-line therapy for colorectal cancer (CRC) <i>R. Earhart, S.V. Cheporov, O.A. Gladkov, M.Y. Biakhov, G.S. Baker, H.B. Breitz</i>	210

Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC) <i>R. DeJager, L. Roman, N. Lopatkin, P. Karlov, H.B. Breitz, R. Earhart</i>	211
A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib <i>A.J. Wagner, S. Yazji, J.A. Morgan, E. Choy, S. George, M. Hohos, M. O'Mara, G.D. Demetri</i>	212
Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder <i>J. Barriuso, G. Daugaard, S. Frentzas, L. Fuglsang, R. Glasspool, A. Krarup-Hansen, R.J. Jones, U. Lassen, L. Sengeløv, J.S. De Bono</i>	213
AP5346 (ProLindac™), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial <i>F. Joly, A. Madroszyk, A. Floquet, D. Gedouin, F. Bourdel, M. Campone</i>	214
Prospective study of erlotinib comparing chemotherapy-naïve non-small cell lung cancer patients having an activating mutation in EGFR gene with those having wild-type EGFR gene <i>D.H. Lee, H.J. Song, Y.M. Lee, Y.H. Choi, S.W. Kim, C. Suh, J.S. Lee</i>	215

PI3Kinase

Abstract number

A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors <i>B. Markman, P.M. LoRusso, A. Patnaik, E. Heath, A.D. Laird, B. van Leeuwen, K.P. Papadopoulos, J. Baselga</i>	216
Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor <i>S. Patel, D. Sampath, M. Belvin, A. Brown, K. Edgar, L. Lensun, P. Moore, L. Salphati, H. Stern, L. Friedman</i>	217
A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors <i>E. Calvo, G. Edelman, J. Baselga, E. Kwak, C. Scheffold, L. Nguyen, G.I. Shapiro</i>	218
NVP-BEZ235, a dual pan-PI3K/mTOR kinase inhibitor, is effective in human lung cancer models harboring EGFR mutations <i>C.R. Schnell, J. Vaxelaire, M. Vogelsanger, M. Hattenberger, F. Stauffer, S. Arnal, C. Garcia-Echeverria, S.M. Maira</i>	219
Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo <i>D. Sampath, M. Belvin, J. Guan, K. Edgar, J. Wallin, W.W. Prior, R. Kassees, P. Moore, S. Patel, L. Friedman</i>	220
A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancer <i>K.R. Auger, L. Luo, S. Knight, G. Van Aller, P.J. Tummino, R.A. Copeland, M. Diamond, D. Sutton, J.R. Jackson, D. Dhanak</i>	221
RNAi screen for Akt regulator <i>B.T. Chua, A. Ullrich, D. Gallego-Ortega, A. Ramirez de Molina, J.C. Lacal, J. Downward</i>	222
Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation <i>P. LoRusso, D. Sarker, D. Von Hoff, R. Tibes, M.K. Derynck, J.A. Ware, Y. Yan, G.D. Demetri, J.S. de Bono, A.J. Wagner</i>	223
Assessment of the antitumor activity of NVP-BEZ235 in experimental renal cell carcinoma models <i>M. Michel, J. Vaxelaire, M. Hattenberger, M. Vogelsanger, F. Stauffer, A. Theuer, C. Stephan, M. Ito, C. Garcia-Echeverria</i>	224
Evaluation of antitumor activity of a novel PI3K inhibitor ZSTK474 by various human cancer xenograft models <i>T. Yamori, M. Okamura</i>	225
Anti-angiogenic activity of a novel PI3K inhibitor, ZSTK474 <i>D. Kong, H. Yoshimi, T. Yamori</i>	226

Scientific programme – details	xxxix
Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors	227
<i>L. Friedman, M. Belvin, J. Le Couter, K. Lin, L. Robillard, D. Sampath, H. Stern, U. Vijapurkar, W. Ye, G. Plowman</i>	
Identification and evaluation of PI3 Kinase as new molecular target in neuroblastoma that critically regulates apoptosis resistance	228
<i>D. Opel, A. Bender, D. Bertele, M. Schneider, C. Poremba, T. Simon, K.M. Debatin, S. Fulda</i>	
Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells	229
<i>N. Alami, Y. Sun, P. De, D.L. Durden, B. Leyland-Jones</i>	
PI3 Kinase inhibitors broadly sensitize glioblastoma cells for death receptor- or chemotherapy-induced apoptosis	230
<i>D. Opel, A. Westhoff, A. Bender, V. Braun, K.M. Debatin, S. Fulda</i>	
Proteasome	Abstract number
Profiling of cancer cell signaling pathways activated by a novel proteasome inhibitor class (syrbactins) in human neuroblastoma	231
<i>A. Bachmann, C. Archer, B. Schellenberg, R. Dudler</i>	
Combined therapeutic effects of bortezomib and fenretinide on Neuroblastoma cell growth, apoptosis, and angiogenesis	232
<i>D. Di Paolo, R. Carosio, F. Pastorino, A. Pezzolo, L.J.V. Galiotta, M. Cilli, D. Ribatti, M. Ponzoni, G. Pagnan</i>	
Bortezomib and Flavopiridol combination induces down regulation of Mcl-1, mitochondrial permeabilization and cell death in ALCL cells	233
<i>E. Zorzi, P. Bonvini, L. Mussolin, G. Basso, A. Rosolen</i>	
NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors	234
<i>R. Kurzrock, P. Hamlin, M. Gordon, D. Hong, S. Fu, A. Younes, A. Hannah, M.A. Palladino, M.A. Spear, C. Aghajanian</i>	
Preclinical and clinical monitoring of cell-and circulating plasma specific proteasome biomarkers after treatment with the proteasome inhibitor, NPI-0052	235
<i>M.A. Palladino, T. Chao, S.T.C. Neuteboom, M. Spear, W. Ma, M. Albitar</i>	
Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D cohort	236
<i>A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M.A. Palladino, G.K. Lloyd, M.A. Spear, M. Millward</i>	
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the inhibition profile of salinosporamides	237
<i>B. Potts, R. Manam, V. Macherla, T. Chao, J. Weiss, M. Groll, K. McArthur, S. Neuteboom, M. Palladino, G.K. Lloyd</i>	
The selective proteasome inhibitor carfilzomib in combination with chemotherapeutic agents improves anti-tumor response in solid tumor xenograft models	238
<i>M. Dajee, M. Aujay, S. Demo, J. Jiang, C. Kirk, S. Lee, F. Parlati, J. Shields, M. Sun, E. Suzuki</i>	

Thursday, 23 October 2008

Plenary session 4		Room ABC
		Abstract number
08:00–09:45	Targeting autophagic pathways Chairs: N. Zaffaroni (Milan, Italy) and R.S. DiPaola (New Brunswick, USA)	
08:05	Oncogenes and tumor suppressor genes control autophagy <i>G. Kroemer (Villejuif, France)</i>	239
08:30	Role of autophagy in cancer resistance <i>S. Kondo (Chiba, Japan)</i>	240
08:55	Novel therapeutic targets within the autophagic pathway <i>W.N. Hait (USA)</i>	241
09:20	Targeting apoptosis-resistant cancer cells through autophagic cell death <i>B. Lu (Nashville, USA)</i>	242
Plenary session 5		Room ABC
		Abstract number
10:15–12:00	Molecular targets – state of the science C Chairs: M.J.A. de Jonge (Rotterdam, The Netherlands) and D.R. Spriggs (New York, USA)	
10:20	Aurora kinase inhibitors: more than one opportunity? <i>B. Laffranchi (Nerviano (Milano), Italy)</i>	243
10:45	Polo-like kinase inhibition in oncology: from bench to bedside <i>P. Schöffski (Leuven, Belgium)</i>	244
11:10	PARP inhibitors in cancer treatment <i>H. Calvert (Newcastle-upon-Tyne, United Kingdom)</i>	245
11:35	Targeting Her: Can resistance to EGFR inhibitors be overcome? <i>B. Burtneess (Philadelphia, USA)</i>	246
Plenary session 6		Room ABC
		Abstract number
14:30–16:00	Proffered paper session Chairs: J. Tomaszewski (Bethesda, USA) and T. Lawrence (Ann Arbor, USA)	
14:30	First-in-Human study of the First-in-Class Hdm2 inhibitor JNJ-26854165 <i>J. Tabernero (Barcelona, Spain)</i>	1LB
14:45	A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole <i>C. Ryan (San Francisco, USA)</i>	2LB
15:00	BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer <i>F. Di Nicolantonio (Candiolo (Torino), Italy)</i>	247
15:15	Notch pathway: a potential new target for the treatment of paediatric ependymomas <i>C. Dantas-Barbosa (Villejuif, France)</i>	248

Scientific programme – details		xli
15:30	Specific activation of microRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia <i>D. Sampath (Houston, USA)</i>	249
15:45	OXA-01, a novel potent mTORC1/TORC2 kinase inhibitor, demonstrates broad spectrum antitumor activity in preclinical models of human cancer <i>P.C. Gokhale (Boulder, USA)</i>	250
Plenary session 7		Room ABC
		Abstract number
16:30–18:15	Targeting protein translation and protein–protein interaction in cancer Chairs: Y. Pommier (Bethesda, USA) and H. Newell (Newcastle Upon Tyne, UK)	
16:30	An approach for targeting protein–protein interactions <i>S. Fesik (Illinois, USA)</i>	251
16:55	Targeting the protein translation factor eIF4E for cancer therapy <i>J. Graff (Indianapolis, USA)</i>	252
17:20	Exploring translation initiation as a therapeutic target <i>J. Pelletier (Montreal, Canada)</i>	253
17:45	Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents <i>S. Wang (Ann Arbor, USA)</i>	254
Poster Sessions		
Apoptosis, necrosis, autophagy		Abstract number
	Cytostatic effect induced by 2-chloroadenosine sensitises PC3 cells to docetaxel <i>I. Bellezza, A. Tucci, C. Conte, A. Minelli</i>	255
	siRNA-mediated Apollon gene silencing induces apoptosis in breast cancer cells via p53 stabilization and caspase-3 activation <i>M. Pennati, A. Lopergolo, P. Gandellini, M. Folini, M.G. Daidone, N. Zaffaroni</i>	256
	Inhibition of autophagy significantly enhances the anticancer activity of SAHA by promoting ubiquitin-conjugated protein accumulation and oxidative stress in colon cancer cells <i>J. Carew, E. Medina, M. Mita, A. Mita, F. Giles, S. Nawrocki</i>	257
	Apoptosis and oxidative stress induced by 2-chloroadenosine in PC3 cell line <i>A. Tucci, I. Bellezza, C. Conte, A. Minelli</i>	258
	Histone deacetylase inhibitors restore caspase-8 expression and overcome TRAIL resistance in cancers with epigenetic silencing of caspase-8 <i>S. Häcker, K.M. Debatin, S. Fulda</i>	259
	A novel paradigm for apoptosis-based therapy of pancreatic cancer: sensitizer/inducer concept of XIAP inhibitors combined with TRAIL <i>M. Vogler, H. Walczak, D. Stadel, F. Genze, P. Möller, T. Simmet, K.M. Debatin, S. Fulda</i>	260
	The Bcl-2 family protein inhibitor, ABT-263, broadly potentiates the cytotoxicity of multiple therapeutic agents in vitro and in vivo <i>C. Tse, J. Chen, S. Jin, V. Abraham, P. Nimmer, S. Tahir, M. Smith, H. Zhang, S. Rosenberg, S. Elmore</i>	261
	Membrane androgen receptor induced apoptosis in prostate cancer cells is regulated by Rho/ROCK/actin signaling <i>C. Stournaras, N. Papadopoulou, I. Charalambopoulos, A. Gravanis, K. Alevizopoulos</i>	262
	IGF-1 receptor stimulation overrides microenvironment-derived tumour cell quiescence <i>A.H. Kyle, J.H.E. Baker, F. Moosvi, A.I. Minchinton</i>	263

A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines	264
<i>K.K. Mann, Z. Diaz, S. Marcoux, M. Kourelis, M. Colombo, P.B. Komarnitsky, G. Abbadessa, W.H. Miller Jr.</i>	
A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis	265
<i>S.V. Holt, A. Logie, B.R. Davies, M. Cockerhill, N. Haupt, N.J. Curtis, D.M. Hickinson, J.S. McKay, P.D. Smith, R.W. Wilkinson</i>	
Apoptosis induction in acute myeloid leukemia by inhibition of MEK and MDM2 is strongly associated with the BH3-only proteins Puma and Bim	266
<i>W. Zhang, M. Konopleva, J. Burks, K. Dywer, W. Schober, J. Yang, T. McQueen, M. Hung, M. Andreeff</i>	
Small molecule XIAP inhibitors enhance TRAIL- or anticancer drug-induced apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance	267
<i>M. Fakler, S. Löder, M. Vogler, I. Jeremias, K.M. Debatin, S. Fulda</i>	
Chemoresistance in ovarian carcinoma: apoptosis checkpoints in taxol-induced molecular pathways	268
<i>A. Luria, M. Wolfson</i>	
Recombinant human epidermal growth factor (rhEGF) inhibits proliferation of cancer cell lines with high level of EGFR expression	269
<i>E.K. Kwon, S.H. Lee, H.G. Wu</i>	
(E)-3-Benzyl-6, 8-dihydroxyoct-2-en-4-one, a novel compound isolated from <i>Streptomyces</i> sp., induces apoptosis in LNCaP cells through mitochondrial-mediated pathway	270
<i>E. Jeon, H. Lim, Y.H. Cho, C.H. Lee, H. Oh</i>	
Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors	271
<i>Y. Mishima, Y. Terui, Y. Mishima, A. Taniyama, R. Kuniyoshi, T. Takizawa, S. Kimura, K. Ozawa, K. Hatake</i>	
Activity of the anti-cancer aptamer AS1411 includes regulation of Bcl-2 family members	272
<i>S. Kuijper, B. Doran, N. Courtenay-Luck, F. McLaughlin, D. Jones</i>	
A novel monosaccharide-based antimetabolite 2,2-difluoro-D-glucose (2-DFG) blocks glycolysis and induces cell death in gliomas	273
<i>L. Antonovic, I. Fokt, M.J. Johansen, S. Szymanski, S. Skora, C.A. Conrad, T. Madden, W. Priebe</i>	
Preliminary evidences for recruitment of innate responses to rectal cancer cell death elicited by neo-adjuvant radio-chemo therapy	274
<i>A. Tamburini, A. Castiglioni, K. Bencardino, E. Orsenigo, V. Russo, L. Albarello, M. Ronzoni, P. Rovere Querini, A. Manfredi, C. Staudacher</i>	
Influence of 2-methoxyestradiol on cell numbers, metabolic activity, morphology, cell cycle progression and gene expression in a breast adenocarcinoma cell line	275
<i>A.M. Joubert, B.A. Stander, S. Marais, J. Janse van Vuuren, F. Joubert</i>	
Platinum (IV) complex LA-12 induces cell cycle arrest and phase specific apoptosis in colon carcinoma cells HCT116	276
<i>O. Blanarova, I. Jelinkova, R. Jendzelovsky, K. Soucek, J. Hofmanova, P. Sova, A. Kozubik</i>	
Expression of the genes involved in apoptosis, proliferation and endoplasmic reticulum stress in ionomycin/PMA treated Jurkat cells	277
<i>K. Stankov, S. Tauszig-Delamasure, G. Bogdanovic, L. Popovic, S. Stankov, N. Sylvius, S. Popovic, P. Mehlen</i>	
New curcumin analogues show enhanced antitumour activity in malignant melanoma cells	278
<i>M. Pisano, S. Cossu, I. Sassu, G. Pagnan, D. Fabbri, M.A. Dettori, G. Palmieri, G. Delogu, M. Ponzoni, C. Rozzo</i>	

Aurora kinase

Abstract number

MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial	279
<i>A. Cervantes, T. Macarulla, S. Roselló, E. Rodríguez-Braun, J. Baselga, J. Tabernero, H. Liu, A. Chakravarty, D. Bowman, O. Eton</i>	

Scientific programme – details	xliii
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States <i>J. Infante, E.C. Dees, R.B. Cohen, H. Burris, B. O'Neil, P. Murphy, Y. Lee, J. Pappas, J.A. Ecsedy, O. Eton</i>	280
Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase <i>E. Dees, J.R. Infante, R.B. Cohen, B. O'Neil, H. Burris, M. von Mehren, G. Gray, K. Galvin, M. Manfredi, O. Eton</i>	281
Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors <i>P. Schöffski, H. Dumez, S.F. Jones, C. Fowst, P. Gerletti, H. Xu, J. Jakubczak, J. Infante, N. Mellaerts, H.A. Burris</i>	282
Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients <i>F. Robert, H. Hurwitz, H. Uronis, C. Verschraegen, R. Advani, A. Chen, G.L. Messerschmidt, N. Havrilla, P. Taverna, M. Evanchik</i>	283
ENMD-2076 exerts antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models <i>J.J. Tentler, E.L.B. Pierce, N.J. Serkova, T.M. Pitts, M.R. Bray, G.C. Fletcher, S.G. Eckhardt</i>	284
MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study <i>J. Tabernero Caturla, A. Cervantes, E. Elez, T. Macarulla, S. Roselló, E. Rodríguez-Braun, B. Stringer, V. Shinde, H. Danaee, O. Eton</i>	285
Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237 <i>M.A. Smith, P.J. Houghton, C.L. Morton, J.M. Maris, J. Courtright, H. Carol, R.B. Lock, Y. Yang, M.G. Manfredi</i>	286
Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity <i>S. Howard, V. Berdini, J. Curry, A.L. Gill, C.J. Richardson, D. Rees, M. Reule, D. Tisi, P. Wyatt, L. Fazal</i>	287
The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines <i>B. Helfrich, M. Garcia, J. Haney, P.A. Bunn Jr.</i>	288
Aurora A kinase inhibition abrogates the mitotic delay induced by microtubule perturbing agents <i>D.R. Wysong, A. Chakravarty, K. Hoar, J.A. Ecsedy</i>	289
Pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Aurora kinases <i>A. Gavai, D. Norris, G. Trainor, G. Vite, Y. Zhao, D. Vyas, J. Tokarski, W. Han, T. Wong, B. Rupnow</i>	290
Cyclins and CDK's	Abstract number
Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis <i>T. Heuer</i>	291
AZD5597, a novel CDK inhibitor causes inhibition of RNA polymerase II mediated signaling and stimulates apoptosis in vitro and in vivo <i>S. Loddick, A. Barker, K. Blades, S. East, J. Foster, C. Geh, C. Jones, A. McGregor, D. Rudge, P.B. Simpson</i>	292
The complexity of cell cycle dynamic of anticancer drugs unraveled by the use of mathematical models suitable for a quantitative assessment of G1, S and G2M checkpoint activities <i>P. Ubezio, M. Lupi, C. Natoli, V. Colombo, M. D'Incalci</i>	293
Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125 <i>R. Alzani, C. Albanese, G. Locatelli, W. Pastori, N. Amboldi, W. Croci, F. Fiorentini, F. Roletto, C. DePonti, C. Mercurio</i>	294
Growth inhibition and induction of apoptosis in anaplastic large cell lymphoma cells treated with the CDK inhibitor flavopiridol <i>P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, G. Basso, A. Rosolen</i>	295

Gene therapy and antisense approaches	Abstract number
Human glioblastoma organotypic slice culture: A novel model for the study of tumor biology and therapeutic response <i>V.K. Puduvalli, J. Xu, Y. Liu, F.F. Lang, S. Prabhu, G. Rao</i>	296
In vivo efficacy and replication dynamics of intravenously administered oncolytic reovirus in nude mice bearing human melanoma xenografts <i>S. Sei, J. Mussio, S. Borgel, M. Hollingshead</i>	297
Autocrine activity of tumor-derived membrane vesicles <i>B.S. Hong, E.J. Choi, E.Y. Lee, Y.J. Yoon, Y.S. Gho</i>	298
Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response <i>C.A. Taylor, B. Ye, Z. Liu, R. Dondero, B. Galton, K.A. Donovan, J.A. Lust, J.E. Thompson</i>	299
Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104 <i>D.C. Singleton, S.P. Syddall, S.Y. Bai, D. Li, W.A. Denny, W.R. Wilson, A.V. Patterson</i>	300
Use of low molecular weight polyethyleneimine conjugated to transferrin for siRNA delivery <i>A. Grabowska, R. Kircheis, J. Kumari, P. Clarke, A. McKenzie, S.A. Watson</i>	301
Identification of novel and potent RNA inhibitors of ErbB3, based on Locked Nucleic Acid (LNA) technology <i>M. Hedtjörn, J. Worm, H. Frydenlund Hansen, T. Koch, H. Ørum, J.B. Hansen</i>	302
Enhanced efficacy of therapy of anti-CD20 antibody with Locked Nucleic Acid antisense oligonucleotide targeting Bcl-2 in human Burkitt's lymphoma xenografts <i>J.B. Hansen, A.M. Høg, M. Hillairet de Boisferon, F. Bichat, H.F. Hansen, J. Worm</i>	303
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer <i>G.R. Simpson, A. Horvath, K. Harrington, R.S. Coffin, H. Pandha</i>	304
Structure–activity relationships for lipophilic dinitrobenzamide mustards as prodrugs for Escherichia coli NfsB nitroreductase <i>S. Sydall, A. Ashoorzadeh, G.A. Atwell, J.B. Smaill, W.R. Wilson, W.A. Denny, A.V. Patterson</i>	305
Targeted suicide gene therapy for small cell lung cancer <i>C. Laulund Christensen, N. Pedersen, H. Skovgaard Poulsen</i>	306
Effects of triple knockdown of cIAP-1, c-IAP-2 and XIAP on prostate cancer cell susceptibility to apoptosis <i>W. Watson, C. Gill, A. O'Neill, C. Dowling, J. Fitzpatrick</i>	307
Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model <i>L. Heinemann, G. Simpson, K. Harrington, A. Melcher, M.C. Coffey, H.S. Pandha</i>	308

Her	Abstract number
Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models <i>M. Treder, S. Ogbagabriel, R. Moor, U. Schulze-Horsel, T. Hettmann, M. Rothe, R. Radinsky, D. Freeman</i>	309
ERBB2/HER2 proteasome–lysosome trafficking and degradation directed by polyubiquitination topology <i>C. Benz, C. Marx, J. Held, B.W. Gibson</i>	310
In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor <i>A. Iwahara, T. Tamura, S. Takagi, H. Kamiguchi, T. Yusa, Y. Ohta</i>	311
EZN-3920, an ErbB3-locked nucleic acid-based RNA inhibitor, potently silences target gene expression in tumor cells grown in vitro and in vivo <i>B. Liao, T. Qu, J. Kosek, S. Castaneda, P. Sapra, Y. Zhang, R. Bandaru, L.M. Greenberger, I.D. Horak</i>	312
Novel inhibitory mechanisms of TAK-285, a new EGFR/ErbB2 dual inhibitor <i>S.A. Shell, K.J. Pry, P. Trusk, R.L. Wappel, Y. Ohta, W. Klohs, S.S. Bacus</i>	313

Scientific programme – details	xliv
Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with other anticancer drugs	314
<i>T. Tamura, S. Takagi, K. Horikoshi, T. Yusa, M. Koyama, H. Tojo, Y. Ohta</i>	
A novel pan-HER ligand trap based on human EGFR (HER1) and HER3 inhibits tumor growth and metastasis in models of human cancer	315
<i>Z. Huang, H.M. Shepard, D. Maneval, P. Jin, M. Beryt, J. Zhang, C. Brdlik, L. Cousens, B. Jorgensen, X. Bai</i>	
ErbB4 suppresses proteasomal degradation of HIF-1 α and promotes survival of cancer cells in hypoxia	316
<i>I. Paatero, S. Heikkinen, E. Iivanainen, T.T. Junttila, P. Heikkinen, O. Kallioniemi, P. Jaakkola, K. Elenius</i>	
Antiproliferative effects of PM02734, a novel marine cyclic peptide compared with currently used Erb-B inhibitors, in a panel of human cancer cell lines characterised for Erb-B expression	317
<i>M. Serova, I. Bieche, A. Ghoul, M. Vidaud, M. Aracil, J. Jimeno, S. Faivre, E. Raymond</i>	
Downregulation of thymidylate synthase by lapatinib: blockage of EGF-induced translocation of nuclear EGFR and HER2	318
<i>H. Kim, S. Han, K. Lee, J. Jung, Y. Yoon, H. Hur, S. Im, D. Oh, Y. Bang, T. Kim</i>	
mTOR	Abstract number
Pharmacodynamics and anti-tumour activity of KU-0063794, a potent and specific inhibitor of mTOR kinase	319
<i>B.R. Davies, C.M. Chresta, P. Dudley, N. Hewitt, M. Brady, M. Jacobsen, I. Hickson, N.M.B. Martin, G.C.M. Smith, M. Pass</i>	
Cellular characterization of OXA-01, a potent and selective dual mTORC1 and mTORC2 kinase inhibitor	320
<i>S.V. Bhagwat, A.P. Crew, P.C. Gokhale, A. Cooke, J. Kahler, Y. Yao, A. Chan, L.D. Arnold, R. Wild, J.A. Pachter</i>	
A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules	321
<i>L. Berk, D. Miller, D. Clapham, J. Loewy, M. Mita, C. Britten, E. Poplin, C.L. Bedrosian, T. Clackson, V.M. Rivera</i>	
mTORC1/mTORC2 selective inhibitors: Identification and characterization of novel small molecules with anti-tumor activity	322
<i>N. Miller</i>	
Dependence on PI3K and RAS–RAF pathways drives the activity of the combination of RAD001 and RAF265, a novel inhibitor of the RAF–MAPK pathway	323
<i>P. Mordant, C. Leteur, J. Bourhis, J.C. Soria, E. Deutsch</i>	
Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models	324
<i>R. Squillace, D. Miller, S. Wardwell, F. Wang, T. Clackson, V. Rivera</i>	
Erlotinib, an EGFR kinase inhibitor, sensitizes mesenchymal-like tumor cells to the actions of OXA-01, a selective non-macrolide inhibitor of mTORC1/mTORC2	325
<i>S. Barr, S. Russo, S. Bhagwat, A. Crew, K. Iwata, D. Epstein, J. Pachter, M. Miglarese</i>	
Dose-finding study of pegylated liposomal doxorubicin (PLD) and the mTOR inhibitor RAD001 (R) in patients (pts) with advanced solid tumors	326
<i>C. Sessa, A. Perotti, A. Delmonte, G. Del Conte, E. Gallerani, A. Fasolo, F. Zanaboni, A. Locatelli, E. Dall'O', L. Gianni</i>	
The serine 2481-autophosphorylated form of mTOR directly binds the mitotic apparatus to control breast cancer cell proliferation: A new role of mTOR as mitotic checkpoint in cell cycle progression	327
<i>J. Menendez, C. Oliveras-Ferraros, A. Vazquez-Martin</i>	
Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer	328
<i>M. Javle, D. Fogelman, A. Kaseb, G. Varadhachary, R. Wolff, J. Abbruzzese</i>	
Vorinostat significantly enhances the antitumor activity of temsirolimus in renal cancer	329
<i>S. Nawrocki, E. Medina, J. Esquivel, S. Smith, K. Oberheu, M. Mita, A. Mita, F. Giles, J. Carew</i>	

Preclinical evidence for the effectiveness of mTOR inhibitor, nanoparticle albumin-bound (nab®) rapamycin as an anticancer agent <i>V. Trieu, T. De, A. Yang, J. Cordia, B. Grim, S. Ci, P. Nguyen, N. Desai</i>	330
New molecular targets	
CYP1A1 activation and pharmacokinetics of a novel chloromethylpyrrololindoline with potential as a tumour selective prodrug <i>A.D. Race, K. Pors, S.D. Shnyder, T.C. Cooper, H.M. Sheldrake, M. Searcey, L.H. Patterson, P.M. Loadman</i>	331
In vivo activity of SGI-1776, an orally active Pim kinase inhibitor <i>D. Bearss, E. Gourley, X.H. Liu, J. Bearss, C. Jones, C. Olsen, D. Vollmer, S. Warner, H. Vankayalapati, P. Severson</i>	332
Effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human osteosarcoma and melanoma tumours <i>M. Pasello, F. Michelacci, F. Pellizzari Tregno, S. Pezzola, G. Filomeni, C. Geroni, M. Serra, G. Federici, C. Lapenta, A.M. Caccuri</i>	333
Molecular modelling and synthesis of novel CYP26A1 inhibitors <i>A.S. Mohamed Aboraia, M.S. Gomaa, C. Simons</i>	334
Identification of potent, selective sphingosine-1-phosphate 1 receptor (S1P1R) antagonists with antitumor activity <i>G. Shankar</i>	335
Targeting MKP1 with novel chemical inhibitors sensitizes melanoma and colon cancer cells to chemotherapeutics in vitro and in vivo <i>S. Kundu, D. Lindner, R. Tuthill, G. Stark, L. Liu, S. Gerson, E. Borden, T. Yi</i>	336
GSK923925A, a novel and selective CENP-E inhibitor, induces pharmacodynamic effects and anti-tumor activity in human Colo205 xenografts <i>D. Sutton, Q. Liu, K.G. Moss, K.W. Wood, J.R. Jackson</i>	337
The ghrelin receptor agonist TZP-101 is a potent anti-tumor-cachexia agent in the human G361 melanoma mouse xenograft model <i>H. Thomas, N. Berthiaume, E. Kneebone, L. Clohs, E. Fournier, M.L. Peterson, E. Marsault, R. Brandt</i>	338
Identification of XL413, a selective Cdc7 kinase inhibitor which induces cell cycle arrest and exhibits potent antitumor activity <i>S. Robertson</i>	339
Anti-tumor activity of YM753, a histone deacetylase inhibitor, against hormone refractory prostate cancer <i>M. Mori, N. Shindoh, N. Amino, A. Kita, Y. Terada, M. Taniguchi, K. Sohda, Y. Sowa, T. Sakai, M. Sasamata</i>	340
CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity <i>D. Drygin, A. Lin, M. Haddach, C. Ho, J. Bliesath, C. Proffitt, M.T.K. Schwaebe, W.A.K. Rice, K.L. Anderes</i>	341
2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography is an early biomarker for tumor growth inhibition of human Colo205 xenografts by the novel and selective CENP-E inhibitor, GSK923295A <i>D. Sutton, R.A. Fleming, K.W. Wood, J.R. Jackson</i>	342
Preclinical validation of the TrpM8 ion channel as a cancer target <i>D.F. Duncan, N. Provost, O. Moreno, M.W. Frohlich, D. Urdal</i>	343
A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors <i>C. van Herpen, F. Eskens, M. de Jonge, I. Desar, L. Hooftman, E. Bone, A. Timmer-Bonte, J. Verweij</i>	344
Myofibrillogenesis regulator 1 as a potential target for cancer therapy <i>R. Shao, K. Ren, Y. Wang</i>	345

Scientific programme – details	xlvii
Myofibroblasts and TGF-beta1 induce upregulation of tumoral LICAM thereby promoting malignant transformation of pancreatic ductal epithelial cells <i>S. Sebens, C. Geismann, M. Morscheck, D. Koch, H. Ungefroren, A. Arlt, M.S. Tsao, M.G. Bachem, P. Altevogt, H. Schäfer</i>	346
Anti-cancer activity of human ribonuclease conjugates with enhanced pharmacokinetic profiles <i>L. Strong, B. Mei, J. Kink, M. Shahan, R. Raines</i>	347
Molecular pharmacology of benzamide riboside and sodium meta arsenite in chronic myeloid leukemia: a preclinical evaluation <i>I. Hariharan, T.R. SantoshKumar, R. Hariharan, J.N. Hiremagalur, M.R. Pillai</i>	348
Vorinostat sensitizes colorectal cancer cell (CRC) lines to AZD6244 and results in synergistic inhibitory effects on proliferation <i>M.P. Morelli, A.M. Meyer, J.J. Tentler, T.M. Pitts, S. Nallapareddy, P.D. Smith, S.G. Eckhardt</i>	349
Measurement of mechanistic markers of histone deacetylase (HDAC) inhibition in samples from clinical trials <i>A. Hardcastle, P. Fong, L. Pickard, J. Arts, M. Janicot, P. Hellemans, J. DeBono, W. Aherne</i>	350
Identification of kinases that are potential molecular determinants of cellular response to radiation using antibody arrays <i>U. Raju, O. Riesterer, D. Molkenhine, L. Milas, K.K. Ang</i>	351
Small molecule antagonists of very late antigen (VLA)-4 inhibit metastasis formation and tumor growth of melanoma <i>M. Valcarcel, F. Aspichueta, R. Hernan, M. Solaun, V. Gutierrez, L. Mendoza</i>	352
Therapeutic potential of YM155 alone and in combination with chemotherapeutics against human non-small cell lung cancer in carcinoma xenograft models <i>K. Yamanaka, T. Nakahara, A. Kita, S. Miyoshi, A. Noda, M. Takeuchi, I. Kinoyama, H. Koutoku, S. Nishimura, M. Sasamata</i>	353
Membrane androgen receptor activation triggers down-regulation of PI-3K/AKT/NF-κB activity and induces apoptotic responses via FasL, caspase 3 and Bad in DU145 prostate cancer cells <i>K. Alevizopoulos, N. Papadopoulou, I. Charalambopoulos, V. Anagnostopoulou, A. Gravanis, C. Stournaras</i>	354
Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449 <i>C.M. Rudin, D.D. Von Hoff, P.M. LoRusso, L. Vernillet, R. Yauch, W.C. Darbonne, H. Mackey, F.J. de Sauvage, J.A. Low, J.C. Reddy</i>	355
MLN4924, a potent and novel small molecule inhibitor of Nedd8 activating enzyme, induces DNA re-replication and apoptosis in cultured human tumor cells <i>M. Milhollen, U. Narayanan, B. Amidon, A. Berger, S. Langston, T. Soucy, P. Smith</i>	356
Effects of 5-fluorouracil (FUra)/leucovorin(LV)-induced DNA damage on the Wnt signaling pathway and downstream targets in human colon carcinoma cell lines (cc) <i>J. Houghton, T.S. Jani, C. Kundu, Y. Jiang, J. DeVecchio, P. Howe</i>	357
18F-FLT-PET for the evaluation of MEK inhibitor AZD6244 <i>I. Desar, R. Gilles, A. Timmer-Bonte, M.V. Cantarini, C.M.L. van Herpen, W.J.G. Oyen, W.T.A. van der Graaf</i>	358
A role for tumor associated macrophages in tumorigenesis <i>A. Bonde, S. Zoller, R. Schwendener</i>	359
Ror2 in renal cell carcinoma: evaluating its role in RCC tumorigenesis <i>T.M. Wright, J.D. Gordan, W.K. Rathmell</i>	360
FGFR4 Y367C: Contributes to a constitutively active FGFR4 and tumour aggressiveness in breast cancer cell line <i>P. Foo, H.K. Ho, S. Streit, J.E. Ruhe, S. Hart, A. Ullrich</i>	361
STAT3 protein binding to supercoiled DNA <i>S. Chasovskikh, O. Timofeeva, A. Dritschilo</i>	362
Fatty acid synthase is a potential therapeutic target in Micro-satellite-unstable colorectal cancers <i>K. Al-Kuraya</i>	363
Obatoclox in SCLC: preclinical evaluation of a BH3 mimetic <i>E. Dean, M. Ranson, D. Fennell, A. Roulston, J. Viallet, M. Berger, C. Dive</i>	364

Effects of PPAR γ agonists on adrenocortical carcinoma in a murine xenograft model <i>M. Mangoni, G. Nesi, S. Gelmini, A. Lombardi, G. Cantini, F. Malentacchi, C. Orlando, M. Luconi, M. Serio, M. Mannelli</i>	365
NAV3 gene aberrations in colorectal cancer target signalling pathways associated with inflammation and the progression of cancer <i>E. Carlsson, K. Ovaska, L. Sipilä, M. Helle, W. Abdel-Rahman, L. Karenko, P. Peltomäki, S. Hautaniemi, K. Krohn, A. Ranki</i>	366
Characterization of cellular resistance mechanisms towards NAD synthesis inhibitors APO866 and CHS-828 <i>U.H. Olesen, M.K. Christensen, F. Björkling, P.B. Jensen, M. Sehested, S.J. Nielsen</i>	367
Discovery and characterization of a new potent orally available Cdc7 inhibitor with anti-tumor activity <i>A. Montagnoli, E. Vanotti, S. Rainoldi, V. Marchesi, A. Ciavolella, V. Croci, V. Patton, C. Albanese, C. Santocanale, J. Moll</i>	368
Molecular sequelae mediating antitumor activity of G-quadruplex-interactive agent TMPyP4 in retinoblastoma cell lines <i>Y. Mikami-Terao, M. Akiyama, T. Kawano, H. Ida, H. Yamada</i>	369
Once weekly rIL-21 in combination with cetuximab as 1st line therapy in CRC. A dose finding safety trial <i>J. Cassidy, A. Anthony, B. Esmarck, E. Ehrnrooth, P. Kristjansen, A. Nihlen, L.T. Hansen, M. Saunders</i>	370
Toxicology and pharmacokinetics of humanized AR47A6.4.2, the first unconjugated therapeutic monoclonal antibody targeting TROP-2 <i>N. Chouinard, S.E. Hahn, A.H.L. Truong, L. Popp, X. Wang, D. Sayegh, V. Harris, B.C. Mak, D.B. Rubinstein, D.S. Young</i>	371
Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumours <i>T. Takahashi, T. Naka, M. Fujimoto, S. Serada, Y. Souma, E. Miyoshi, S. Hirota, T. Nishida</i>	372
HP1 γ epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers <i>M. Takanashi, K. Oikawa, T. Mizutani, N. Gotoh, M. Kuroda</i>	373
Efficient LNA-mediated antagonism of the oncogenic microRNA-155 in vitro and in vivo <i>J. Worm, J. Stenvang, S. Obad, M. Hedtjärn, E.M. Strarup, J.B. Hansen, S. Kauppinen</i>	374
Annexin I regulation of breast cancer cell proliferation <i>T. Khau, M. Schuliga, T. Harris, A. Stewart</i>	375
NAV3 – a novel cancer biomarker <i>L. Sipilä, L. Karenko, L. Siggberg, W. Abdel-Rahman, M. Helle, V. Häyry, S. Knuutila, P. Peltomäki, A. Ranki, K. Krohn</i>	376
Selective inhibition of Stat3 expression induces apoptosis in human cutaneous T-lymphoma cell line Hut78 <i>N.K. Verma, A.M. Davies, A. Long, D. Kelleher, Y. Volkov</i>	377
CD147 expression correlates with monocarboxylate transporters 1 and 4 in cervical carcinoma <i>C. Pinheiro, A. Longatto-Filho, S.M.M. Pereira, D. Etlinger, M. Moreira, L. Jubé, F. Schmitt, F. Baltazar</i>	378
Phase I	Abstract number
A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) <i>R. Kurzrock, S. Sherman, D. Hong, C. Ng, J. Frye, L. Janisch, M.J. Ratain, R. Salgia</i>	379
Transcriptional and metabolic response associated with acute doxorubicin cardiotoxicity in perfused rat heart <i>M. Tokarska-Schlattner, E. Lucchinetti, M. Zaugg, L. Kay, S. Gratia, R. Guzun, V. Saks, U. Schlattner</i>	380
Detecting EGFR mutations in NSCLC by mutant specific antibodies <i>J. Yu, S. Kane, J. Wu, D.Q. Li, X.M. Zhou, K. Crosby, H. Herbert, T.L. Gu, R. Polakiewicz, M. Comb</i>	381

Scientific programme – details	xlix
Comparison of phase I trial (PIT) abstract quality between the EORTC-NCI-AACR and ASCO meetings <i>J. Ho, E. Strevel, N. Chau, G.R. Pond, A. Murgo, P. Ivy, L.L. Siu</i>	382
A phase I study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors <i>G.K. Schwartz, S. Yazji, D.S. Mendelson, M.A. Dickson, S.H. Johnston, E.W. Wang, P. Shannon, L. Pace, M.S. Gordon</i>	383
Effect of selection of QTc formula on eligibility of patients for phase I cancer clinical trials <i>M. Benjamin, D. Casa, W. Tembe, B. Piper, S. Anthony, R. Ramanathan, R. Tibes, G. Jameson, D. Von Hoff, M. Borad</i>	384
A phase I safety, pharmacokinetic and pharmacodynamic study of carfilzomib, a selective proteasome inhibitor, in subjects with advanced solid tumours <i>K.P. Papadopoulos, J.R. Infante, A.F. Wong, L.A. Kunkel, A. Patnaik, M. Goldston, S. Mersch, S.D. Demo, A. Tolcher, H.A. Burris</i>	385
Pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose (MTD) in a twice daily (bid) dosing schedule <i>T.A. Yap, J. Barriuso, S. Frentzas, R. Riisnaes, J. Clark, J. Dukes, A. Futreal, R.E. Savage, F. Chai, J.S. de Bono</i>	386
Operation strategy of Phase I trials <i>N. Ishizuka, T. Taniguchi</i>	387
Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma <i>S. Postel-Vinay, S. Okuno, S. Schuetze, M.L. Paccagnella, D. Yin, A. Gualberto, F. Worden, P. Haluska, J. De Bono, M. Scurr</i>	388
Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors <i>I. Duran, L.L. Siu, C. Kollmannsberger, L. Gontovnick, S. Leong, L. Wang, C. Braun, T. Borgford, S.G. Eckhardt, L. Gore</i>	389
A Phase I dose-escalation study of XL228, a potent IGF1R / Src inhibitor, in patients with advanced malignancies <i>C. Britten, D.C. Smith, L.A. Bui, D.O. Clary, H.I. Hurwitz</i>	390
A Phase I randomized trial to assess the effects of Src inhibitor AZD0530 on renal function in healthy volunteers <i>R. Chetty, N. Dalton, M. Rimmer, N. Cockburn, I. Smith, A. Swaisland, J. Hargreaves, M. Stuart</i>	391
A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib <i>J.C. Soria, E. Felip, R. Herbst, N. Hannah, S. Laurie, J.P. Armand, F. Shepherd, D. Berman</i>	392
First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies <i>J.E. Ang, B. Hauns, A. Mais, A. Parker, R. Lal, D. Olmos, M. Mollenhauer, A. Walz, J.S. de Bono</i>	393
Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors <i>H. Murakami, N. Yamamoto, N. Boku, K. Yamazaki, N. Yamamoto, Y. Yamada, K. Yamada, T. Puchalski, E. Shin, T. Tamura</i>	394
Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies <i>A. Tse, S. Yazji, A. Naing, D. Matthews, G. Schwartz, K. Lawhorn, R. Kurzrock</i>	395
Effect of oral (PO) casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (IV) docetaxel <i>L. Adams, B. Johnson, J. Bauman, P. Lebowitz, K. Zhang, T. Webb, E. Gartner, R. Hohl, U. Dandamudi, L. Lewis</i>	396
A phase I dose escalation and pharmacokinetic study of the novel mitotic checkpoint inhibitor GSK923295A in patients with solid tumors <i>R.A. Fleming, K.D. Holen, T.L. Cyr, B.M. Johnson, J.L.S. Gauwin, J.J. Lager, B. Williams, D.B. Alberti, B.L. Weber, V. Chung</i>	397

Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours <i>N. Lewis, R.B. Cohen, Y. Nishida, H.I. Hurwitz, C. Arrowwood, H.E. Uronis, F. Gamza, C. Longley, A. Buchbinder, J. Figueroa</i>	398
A Phase 1 dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of intravenous LY2275796 (LY), an eIF-4E antisense oligonucleotide (ASO) in patients with advanced solid tumors <i>G.R. Simon, M. Fishman, A.M. Dellaportas, D. Sullivan, L.H. Brail, V. Andre, S. Callies, U. Aytac, D. Hong, Y. Oh</i>	399
Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer <i>L.S. Rosen, M.S. Gordon, H.I. Hurwitz, D.S. Mendelson, D. Kleinzweig, B.J. Adams, C.P. Theuer</i>	400
A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies <i>H.A. Wakelee, S.K. Padda, L. Chhatwani, M. San Pedro-Salcedo, Y. Krupitskaya, L. Musib, J.E. Latz</i>	401
A phase I study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies <i>S. Leong, C.L. Obryant, W.A. Messersmith, S. Diab, M.A. Kane, S. Nallapreddy, C. Weekes, J. Spratlin, J. Call, S.G. Eckhardt</i>	402
Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial <i>A.W. Tolcher, M. Mita, M. Gordon, L. Rosen, A. Patnaik, G.D. Fine, G.S. Choy, G.I. Berk</i>	403
A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors <i>W. Kelly, D. Petrylak, G. Blumenschein, U. Lassen, P. Buhl Jensen, J. DeBono</i>	404
Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers <i>S.J. Hotte, H.W. Hirte, P. Moretto, A. Iacobucci, D. Wong, W. Korz, W.H. Miller</i>	405
IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study <i>S. Krishnamurthi, P.H.B. Goncalves, F. Fox, N. Hall, E. Rowinsky, J. Schwartz, H. Youssoufian, P. LoRusso</i>	406
Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies <i>D. Zain, D. Bongero, A. Goy, R. Orłowski, J. Hainsworth, B. Afanasyev, M.M. Chen, R. Escandon, Y. Mao, O.A. O'Connor</i>	407
Phase 1 study of recombinant human Interleukin-21 (rIL-21) in combination with sunitinib in patients with stage IV renal cell carcinoma <i>V. Grünwald, I. Desar, J. Haanen, W. Fiedler, M.B. Olsen, C.M.L. van Herpen</i>	408
A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies <i>M.J. Pishvaian, A. Wagner, J. Deeken, A.R. He, J. Hwang, S. Malik, I. Cotarla, G. Demetri, J.L. Marshall, S. Wojtowicz-Praga</i>	409
Phase I pharmacodynamic (PD) and pharmacokinetic (PK) analysis of the sorafenib (S) and erlotinib (E) combination in patients with advanced solid tumors <i>C. Le Tourneau, I. Duran, E. Chen, L. Wang, M. Tsao, D. Hedley, N. Phan, T. Do, U. Metser, L. Siu</i>	410
A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors <i>R. Salgia, A. Peterson, S. Eppler, W. Yu, B. Polite, D. Geary, E. Wesolowski, M. LaRosiliere, M. Ratain, M. Sovak</i>	411

Scientific programme – details	li
A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug <i>G.J. Weiss, J.R. Infante, M. Borad, V.K. Langmuir, S. Kroll, D. Jung, R. Tibes, E.G. Chiorean, S.F. Jones, H.A. Burris</i>	412
A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies <i>W.P. Yong, B.C. Goh, K. Ethirajulu, P. Yeo, O. Otheris, S.M. Chao, R. Soo, W.L. Yeo, E. Seah, J. Zhu</i>	413
A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors <i>M.S. Gordon, L.S. Rosen, F. Robert, D.S. Mendelson, D. Kleinzweig, B.J. Adams, C.P. Theuer</i>	414
Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations <i>Y. Lee, O. Eton, J. Pappas, S. Chen, M. Paton, E.C. Dees, S. Jones, R.B. Cohen, A. Cervantes, J. Taberero</i>	415
Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety profile and maximum tolerated dose <i>A.R. Tan, T. Mekhail, M.J. Edelman, L.C. Iacono, M. Messina, O.C. Trifan</i>	416
Phase I study of E7389/Gemcitabine combination in patients with advanced solid tumours <i>R. Goel, L. Vidal, S. Welch, S. Laurie, L. Siu, D. Jonker, R. Srinivasan, L. Wang, C. Fortin, A.M. Oza</i>	417
A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPT) <i>M.J. Pishvaian, J.H. Hwang, S. Malik, A.R. He, J.F. Deeken, C.B. Kelso, K. Dorsch-Vogel, M.S. Berger, J.L. Marshall</i>	418
A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours <i>M. Sorensen, J. Tjørnelund, P.B. Jensen</i>	419
A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS) <i>A.T. Brunetto, A. Krarup-Hansen, O.S. Nielsen, A. Norman, A. Safwat, J. Tjørnelund, I. Judson</i>	420
Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour <i>T. Mukohara, S. Nagai, Y. Nambu, K. Yoshizawa, H. Minami</i>	421
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours <i>N. Okamoto, K. Hatake, N. Yamamoto, S. Takahashi, N. Boku, K. Kobayashi, K. Sakatani, T. Hirashima, K. Matsui</i>	422
Phase I dose escalation study of NK012, polymer micelle of irinotecan metabolite SN-38, in patients with advanced cancer <i>D. Toshihiko, N. Fuse, A. Ohtsu, Y. Matsumura, T. Hamaguchi, K. Kato, Y. Shimada, T. Nakajima, Y. Yamada, M. Takanashi</i>	423
ANG1005, an Angiopep-2/paclitaxel conjugate: the first clinical trial in patients with advanced cancer and brain metastases: Preliminary safety and tolerability data <i>R. Kurzrock, S. Fu, A.C. Mita, Z. Guo, C. Allison, D. Bouchard, K.M. Elian, A. Neale, J.P. Castaigne, J. Sarantopoulos</i>	424
ANG1005: Preliminary clinical safety and tolerability in patients with recurrent malignant glioma <i>J.P. Castaigne, K.M. Elian, D. Bouchard, A. Neale, S. Rosenfeld, J. Drappatz, M. Groves, P. Wen, P. Bento, B. Lawrence</i>	425
Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules <i>J. Kissling, G.D. Fine, G.S. Choy, C. Eddy, G.I. Berk</i>	426
Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study <i>A. Patnaik, M. Goldston, C. Takimoto, A. Tolcher, K. Papadopoulos, T. Bekaii-Saab, B. Kleiber, F. Gamza, C. Longley, A. Buchbinder</i>	427

A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors	428
<i>Y. Onozawa, N. Boku, A. Fukutomi, A. Ohtsu, T. Doi, T. Yoshino, W. Koizumi, S. Tanabe, T. Sasaki</i>	
Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors	429
<i>H. Hurwitz, P. LoRusso, G.I. Shapiro, A. Wolanksi, J. Chemidlin, E. Masson, S. Syed, G. Kollia, K. Conlon</i>	

Polo kinases Abstract number

Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer	430
<i>D. Rudolph, M. Steegmaier, M. Hoffmann, M. Grauert, A. Baum, J. Quant, P. Garin-Chesa, G. Adolf</i>	
A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors	431
<i>S. Blagden, D. Olmos, R. Sharma, J. Barriuso, H. Medani, M. Versola, S. Murray, D.A. Smith, M.M. Dar, J.S. deBono</i>	
A small molecule allosteric inhibitor of Polo-like kinase 3 induces apoptosis and disrupts the integrity of the mitotic spindle apparatus in cancer cells	432
<i>S.K. Horrigan, I. Lonskaya, P. Adisheshaiah, N.E. Ohler, Z. Weaver, Z. Wang, D.K. Bol, T. Lawrence, S. Chellappan, J.W. Strovel</i>	
Crystal structures of Plk1 kinase domain in complex with ATP-competitive inhibitors	433
<i>I. Beria, J.A. Bertrand, M. Caruso, M. Fasolini, N. Mongelli, R. Perego, S. Re Depaolini, P. Storici, B. Valsasina, R. Bossi</i>	
Antitumoral activity of pyrazoloquinazoline derivatives as potent oral Plk-1 specific inhibitors	434
<i>I. Beria, B. Valsasina, M.G. Brasca, M. Caruso, R.D. Ferguson, J. Lansen, J. Moll, E. Pesenti, H. Posteri, M. Rocchetti</i>	

Protein – protein interaction Abstract number

Therapeutic potential of a potent and selective antagonist of the MDM2-p53 interaction (MI-219) in combination with traditional chemotherapy	435
<i>S. Shangary, D. McEachern, M. Liu, R. Miller, S. Qiu, Z. Nikolovska-Coleska, S. Wang</i>	
The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain	436
<i>H. Kadri, T.C. Dale, K.B.R. Ewan, A.D. Westwell</i>	
MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines	437
<i>X. Lu, J. Liu, A. Watson, I.R. Hardcastle, R.J. Griffin, B.T. Golding, D.R. Newell, J. Lunec</i>	

Telomerase-targeting agents Abstract number

Pharmacodynamics (PD) of GRN163L in a Phase I study in refractory, solid tumors	438
<i>M. Ratain, J.A. Smith, F.M. Benedetti, L. Elias, P. LoRusso</i>	
The cytotoxic activity of the telomere binding agent KML001 in non-small cell lung cancer cells is dependent on telomere length and p53 status and is enhanced by cisplatin	439
<i>P. Phatak, M. Edelman, H. Hendriks, A. Burger</i>	
Integrative biological studies of antitumour agents	440
<i>L.A. Johnson, A.E. Willis, H.M. Byrne, C.A. Laughton</i>	
The G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors	441
<i>A. Biroccio, M. Scarsella, A. Rizzo, M. Mottolese, M. D’Incalci, A. Stoppacciaro, M. Stevens, E. Gilson, G. Zupi, C. Leonetti</i>	

Scientific programme – details	liii
Novel small molecule inhibitors of telomerase <i>A. Adekunle, H.R. Evans, V.A. Phillips, D. Pletsas, R.T. Wheelhouse, S.M. Parkin, D.A.L. Watt, D.T.S. Sharpe, R.M. Phillips</i>	442
Tubulin-interacting agents	Abstract number
Reduced expression of the epithelial specific ETS factor ESE-3 is associated with resistance to taxanes in prostate cancer cells <i>R. Cangemi, S. Pellini, P. Kunderfranco, A. Malek, C.V. Catapano, G.M. Carbone</i>	443
BAL27862: a novel tubulin interacting agent with activity in multidrug resistant tumors and potential as a vascular disruption agent <i>H.A. Lane, J. Pohlmann, F. Bachmann, U. Lüdi, S. Mathews, J. Heim</i>	444
Class III beta-tubulin overexpression in non-small cell lung, breast and prostate carcinoma xenografts confers innate or acquired resistance to taxanes and sensitivity to ixabepilone <i>F. Lee, K. Covello, M. Kimler, R. Lenhart, Y. She, S. Platero, R. Kramer</i>	445
A phase I study of eribulin mesylate (E7389) in patients with refractory cancers <i>H. Minami, T. Mukohara, S. Nagai, H. Mukai, M. Namiki</i>	446
ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma <i>R. Woessner, B. Tunquist, E. Chlipala, M. Humphries, D. Trawick, A. Cox, P. Lee, J. Winkler, D. Walker</i>	447
NKTR-105, a novel PEGylated-docetaxel, demonstrates superior anti-tumor activity compared to docetaxel in human non-small cell lung and colon cancer xenografts <i>R. Wolff, S. Routt, J. Riggs-Sauthier, W. Zhang, H. Persson, R.K. Johnson</i>	448
In vivo evaluation of ALB 109564, a novel tubulin inhibitor with improved efficacy over existing members of the Vinca alkaloid class <i>M. Wolf, R.K. Johnson, D. Xie, A. Avrutskaya, R. Mullin, B. Godfrey, I. Scott</i>	449
NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522 <i>S. Neuteboom, E. Medina, M.A. Palladino, M.A. Spear, G.K. Lloyd, S. Nawrocki</i>	450
Prednisolone abrogates patupilone (EPO906)-induced diarrhoea in rats without impacting on patupilone PK or efficacy <i>P. McSheehy, M. Becquet, J. Boisclair, M.N. Bizot</i>	451
Tubulin acetylation and the antimotility effects of tubulin-targeting agents <i>K. Bonezzi, B. North, C. Manzotti, A. Riva, E. Verdin, R. Giavazzi, G. Taraboletti</i>	452
Antitumor efficacy of a new taxane, nanoparticle albumin bound ABI-013 <i>C. Tao, V. Trieu, Q. Wang, T. De, S. Ci, P. Nguyen, N. Desai</i>	453
Combretastatin-induced changes in normal vascular physiology and the therapeutic implications <i>M. Horsman, A. Bohn, M. Skals, T. Wang, M. Busk</i>	454
Comparison of the effect of patupilone (EPO906) and other cytotoxic drugs on interstitial fluid pressure (IFP) and growth of human ovarian (1A9 and 1A9PTX10) and lung (A549 and A549.B40) xenografts in athymic mice <i>P.M. McSheehy</i>	455

Friday, 24 October 2008

Plenary session 8

Room ABC
Abstract number

08:00–09:45	RNA based technologies for target identification, validation and treatment Chairs: E.H. Rubin (New Jersey, USA) and P. Ho (Collegeville, USA)	
08:00	Development of practical delivery systems for therapeutic small RNAs <i>A. Aigner (Marburg, Germany)</i>	456
08:25	Identifying mechanisms of drug resistance using large scale genetic screens <i>R. Bernards (Amsterdam, The Netherlands)</i>	457
08:50	High-throughput RNAi screening using cell microarray technology <i>O. Kallioniemi (Helsinki, Finland)</i>	458
09:15	microRNA and therapeutic applications <i>D. Cohen (North Brunswick, USA)</i>	459

Plenary session 9

Room ABC
Abstract number

10:15–12:00	Imaging molecular targets Chairs: J.L. Tatum (Rockville, USA) and C. Kollmannsberger (Vancouver, Canada)	
10:15	Update on imaging tumor proliferation with PET <i>A. Shields (Detroit, USA)</i>	460
10:40	Hypoxia imaging <i>K.A. Krohn (Seattle, USA)</i>	461
11:05	Apoptosis imaging <i>H. Strauss (New York, USA)</i>	462
11:30	Applications of nanotechnology and molecular probes in cancer imaging <i>T.J. Meade (Evanston, USA)</i>	463

Plenary session 10

Room ABC
Abstract number

14:00–15:45	Challenges in the development of antibodies and antibody conjugates Chairs: C.H. Takimoto (Radnor, USA) and J.M. Ford (Stanford, USA)	
14:00	Antibodies/antibody conjugates in development <i>D. Chang (Thousand Oaks, USA)</i>	464
14:25	Challenges in the development of antibody drug conjugates <i>S. Lutzker (South San Francisco, USA)</i>	465
14:50	Challenges in targeting proteases as anti-cancer therapy <i>C. TenHoor (Cambridge, USA)</i>	466
15:15	The targeted oncology platform at ImClone Systems: novel receptor blocking antibody therapeutics and approaches <i>E.K. Rowinsky (New York, USA)</i>	467

Closing Ceremony**Room ABC**

15:45–15:50	Closing remarks	
	<i>J. Doroshow</i>	NCI
	<i>E.H. Rubin</i>	AACR
	<i>P. Schöffski</i>	EORTC

Poster Sessions**Antimetabolites**

Abstract number

The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2'-F-ara-deoxyuridine <i>P. Phatak, C.M. Daniels, A.F. Shields, J.M. Collins, P.M. LoRusso, A.M. Burger</i>	468
The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types <i>I.N. Fleming, A.K. Choudhary, R.H. Mackay, S.R. Green, S. Davis</i>	469
Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma <i>M. Watson, A. Roulston, H. Chan, D. Goulet, D. Bedard, E. Turcotte, G. Shore, J. Viallet, P. Beauparlant</i>	470
Plasma pharmacokinetics of CP-4055 in patients with acute myeloid leukaemia at the recommended phase II dose <i>S. Hagen, S.M. O'Brien, T.F. Jacobsen, H.M. Kantarjian, M.L. Sandvold, F. Giles</i>	471
The IMPDH inhibitor AVN944 synergizes with Clofarabine to induce cell death in myeloid cancer cell lines <i>J. Strovel, T. Lawrence, P. Natarajan, J.M. Hamilton, D.K. Bol</i>	472

Bioreductive agents

Abstract number

The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase) <i>A.V. Patterson, C.P. Guise, M. Abbattista, W. van Leeuwen, S.M. Pullen, D.M. Ferry, W.A. Denny, P. Guilford, W.R. Wilson</i>	473
Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models <i>R.S. Singleton, S.M. Pullen, D.M. Ferry, C.P. Guise, A.V. Patterson, W.R. Wilson</i>	474

Differentiation

Abstract number

Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation and inhibition of proliferation <i>Y.A. Young, M.H. Kang, J.S. Kim, J.H. Seo</i>	475
Involvement of the helix-loop-helix protein ID-1 in granulocytic differentiation of human myeloblastic leukemia cells <i>T. Shimizu, K. Takeda</i>	476

DNA repair

Abstract number

Sequence-selective inhibition of the DNA binding potencies of Pit-1 and Brn-3 transcription factors by phenyl-furan-benzimidazole DNA ligands <i>P. Peixoto, S. Depauw, M.P. Hildebrand, D.W. Boykin, W.D. Wilson, M.H. David-Cordonnier</i>	477
Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repair <i>R. Kimmel, J. Kumer, D. Stockett, R. Hawtin, P. Taverna, J. Silverman</i>	478

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications <i>T.D. Bradshaw, J. Zhang, M.F.G. Stevens, C.A. Laughton, S. Madhusudan, P. Kirschmeier</i>	479
MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting rad51 is not toxic to human primary marrow stem cells at clinically relevant concentrations <i>R. Joshi, S. Kanekal, S. Redkar, G. Berk</i>	480
Expression of genes involved in DNA damage response pathways in ovarian cancers <i>G. Damia, M. Ganzinelli, P. Mariani, R. Fruscio, C. Mangioni, M. Broggin</i>	481
Pre-clinical pharmacology of the novel PARP inhibitor, AZD2281 (KU-0059436) <i>A.N. Cranston, S. Moore, L. Beaudoin, A. Lau, L. Lewis, L. Copsey, M.J. O'Connor, K.A. Menear, G.C.M. Smith, N.M.B. Martin</i>	482
Immunohistochemical DNA repair expression profile breast cancer: correlation with clinical-pathological features <i>S. Costa, F. Milanezi, M. Duarte, J. Paredes, A.L. Correia, A. Longatto-Filho, F. Schmitt</i>	483
Drug resistance and modifiers	Abstract number
EGFR mutations and gefitinib affinity: molecular insights from in silico experiments <i>S. Pricl, G.M. Pavan, M. Fermiglia, E. Tamborini, M.A. Pierotti, S. Pilotti</i>	484
Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells <i>A. Kong, V. Calleja, P. Leboucher, A. Harris, P. Parker, B. Larjani</i>	485
Combined targeting of DNA repair and AKT survival pathways enhance temozolomide therapeutic activity in melanoma <i>L. Liu, Y. Miao, A. Bulgar, B. Jacobs, M. Schluchter, E. Borden, S. Gerson</i>	486
An inducible expression system to study the EGFR-T790M gefitinib-resistance mutation in a human lung cancer cell line <i>F. Moreira-Leite, A. Welman, R.A.R. Roberts, C. Dive</i>	487
MDR-transporters, namely Pgp, MRP1 and vault protein LRP, as poor predictive markers of tamoxifen efficiency in estrogen receptor positive breast cancer tumours <i>E.A. Dudko, E.A. Bogush, T.A. Bogush, V.J. Kirsanov, G.Y. Tchemeris, M.I. Davydov</i>	488
Casein kinase II modulates topoisomerase II alpha nuclear export and drug sensitivity of multiple myeloma cells <i>J.G. Turner, J. Dawson, B. Fang, J. Koomen, D.M. Sullivan</i>	489
Examination of the mechanisms associated with bortezomib-resistance in human multiple myeloma cell lines <i>D.J. Kuhn, R.Z. Orlowski</i>	490
AF1q enhancement of doxorubicin induced apoptosis in human squamous carcinoma A431 cells <i>N.N. Co, W.P. Tsang, T. Wong, T.Y. Tsang, T.T. Kwok</i>	491
Role of human epidermal receptor targeted therapies in chemo-sensitization of oesophageal adenocarcinoma cells <i>L. Campbell, S. Van Schaeybroeck, J. Kyula, M.M. Eatock, P.G. Johnston</i>	492
Manipulating prostate cancer cell susceptibility to docetaxel and novel titanocene analogues induced apoptosis <i>C. Dowling, S. Cuffe, M. Tacke, J. Fitzpatrick, W. Watson</i>	493
Cellular and molecular patterns associated with sensitivity and resistance to enzastaurin in human cancer cells <i>A. Ghoul, M. Serova, I. Bieche, M. Videau, K.A. Benhadji, S. Faivre, E. Raymond</i>	494
Enhanced expression of Annexin IV in clear cell carcinoma of the ovary and its association with chemo-resistance <i>A. Kim, S. Serada, K. Iwahori, Y. Souma, T. Takahashi, T. Naka</i>	495
Regulation of Nrf2-antioxidant system and glutathione transferases by 5-fluorouracil in colon cancer HT-29 cells: potential implication in drug resistance <i>H. Akhdar, P. Loyer, C. Rauch, A. Guillouzo, F. Morel</i>	496

Scientific programme – details	lvii
Different patterns in telomerase activity (TA) change after acquisition of resistance to tamoxifen in hormonal receptor positive breast cancer cells <i>W. Park, J. Joo, Y. Jung, H. Jeon</i>	497
Interleukin-8 signalling contributes to chemotherapy resistance in colorectal cancer cells <i>C. Purcell, C. Wilson, O. Oladipo, R.H. Wilson, P.G. Johnston, D.J. Waugh</i>	498
The effects of hypoxia on the sensitivity of glioma cells to gemcitabine treatment <i>R. Foster, S. Mead, K. Grimshaw</i>	499
Molecular and cellular consequences of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) direct interaction with the S23906–1/DNA adduct <i>G. Lenglet, S. Depauw, D. Mendy, A. Pierré, M.H. David-Cordonnier</i>	500
MicroRNA expression profiling in paclitaxel-resistant ovarian cancer cell line: miR-31 is involved in the acquired resistance to paclitaxel <i>M. Hassan, H. Watari, A. Abdel Kader, T. Mitamura, N. Sakuragi</i>	501
Modification of cisplatin administration schedule in FLEP preoperative chemotherapy improved response to the chemotherapy in patients with locally-advanced esophageal cancer <i>T.A. Bogush, B.E. Polotskiy, E.A. Bogush, I.A. Pokataev, E.O. Ignatova, S.A. Tjulandin, M.I. Davydov</i>	502
ABCG2 transporter gene expression in childhood rhabdomyosarcoma <i>H.P. McDowell, S. Marsilio, P. Altavista, S. Bosco, A. Donfrancesco, A. Inserra, P.D. Losty, C. Dominici</i>	503
Monoclonal antibodies and targeted toxins/nuclides	Abstract number
GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion <i>C. Klein, F. Herting, T. Friess, C. Gerdes, A. Nopora, S. Bauer, R. Grau, E. Moessner, J. Dal Porto, P. Umana</i>	504
Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases <i>A. Macias, E. Neninger, E. Santiesteban, J. Figueredo, A. Hernandez, F. Aguirre, N. Aguilera, T. Crombet</i>	505
The apogenic anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in breast and pancreatic cancer and targets cancer stem cells in acute myeloid leukemia <i>J. Menendez, L. Jin, A.G. Poepl, K. O'Reilly, R.H. Brunet, J. Grabell, A.K. Gupta, J.E. Dick, D.S. Pereira, D.S. Young</i>	506
Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE in rituximab sensitive and resistant lymphomas <i>H.P. Gerber, I. Stone, M. Kung-Sutherland, J. Miyamoto, N. Okeley, S.C. Alley, D.L. Meyer, D. Sussman, P. Senter, I.S. Grewal</i>	507
PDL192, a novel, humanized antibody to TWEAK receptor, shows potent anti-tumor activity in preclinical models <i>P. Culp, D. Choi, J. Yin, S. Tan, D. Chao, M. Su, M. Sho, R. Steinle, E. Hsi, V. Ramakrishnan</i>	508
Efficacy of AMG 479, a fully human anti-IGF-1R monoclonal antibody, against xenograft models displaying genetic alterations in Ras/Raf, PI3K/PTEN and p53 pathways <i>P.J. Beltran, G. Moody, P. Mitchell, Q. Le, B. Belmontes, E. Cajulis, Y.A. Chung, F. Calzone, R. Radinsky</i>	509
Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours <i>P. Woll, F. Fossella, M. O'Brien, Y. Clinch, K. Donaldson, J. O'Keeffe, S. Zildjian, R. Fram, A. Qin, P. Lorigan</i>	510
Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies <i>E. Chiorean, C. Sweeney, H. Youssoufian, F. Fox, T. Katz, E. Rowinsky, R. Amato</i>	511

Interim results from a Phase 1/2 study of volociximab in combination with liposomal doxorubicin in patients with advanced epithelial ovarian or primary peritoneal carcinoma that relapsed after platinum/taxane chemotherapy <i>P. Antonella, C. Sessa, A. Delmonte, G. Del Conte, A. Fasolo, E. Dall'O', F. Zanaboni, S. Watkins, K. Smith, L. Gianni</i>	512
Anti-tumor effect of an anti-human Müllerian Inhibiting Substance type II receptor antibody in a nude mouse model for granulosa cell tumors: a new targeted therapy for ovarian cancer <i>N. Kersual, V. Garambois, I. Salhi, C. Larbouret, F. Bibeau, C. Mollevi, T. Chardès, A. Pèlerin, I. Teulon</i>	513
A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer <i>A. Tolcher, J. Watermill, R.A. Mastico, R.J. Lutz, J. O'Keeffe, S. Zildjian, A. Phan, A. Mita, A. Qin</i>	514
Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel <i>T. Junttila, C. Fields, G. Li, L. Crocker, K. Parsons, L. Berry, K. Totpal, G. Lewis Phillips, M. Sliwkowski</i>	515
Efficacy of EGFR and IGF-1R antibody therapy is independent of PTEN status in a selection of tumor models <i>D. Deevi, D. Burtrum, M. Melchior, L. Witte, D.L. Ludwig, J.R. Tonra</i>	516
A monoclonal antibody (AR36A36.11.1) with potent in vivo efficacy in multiple human cancer models targets CD59 <i>B. Mak, F. McConkey, N. Feng, K. O'Reilly, S.W. Fung, M. Wang, S. Chau, S.E. Hahn, D.S. Pereira, D.S. Young</i>	517
Novel antibody-maytansinoid conjugates with efficacy against multidrug resistant tumors <i>Y. Kovtun, C. Audette, E. Maloney, M. Mayo, G. Jones, H. Erickson, S. Wilhelm, R. Singh, V. Goldmacher, R. Chari</i>	518
A phase 2, single-arm study of volociximab (an anti- $\alpha 5\beta 1$ integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer <i>C.M. Matthews, S.N. Ho, M. Barve, K.M. Bell-McGuinn, L. Gilbert, R.T. Penson, E. Lengyel, S. Weymer, K. Gilder, R.J. Schilder</i>	519
A monoclonal antibody targeting Trop-2 exhibits anti-tumor efficacy in human cancer models as a monotherapy and demonstrates efficacy in combination therapy <i>A.H.L. Truong, M. Wang, V. Harris, N. Aziz, J. Grabell, L. Popp, M. Amoozgar, S.E. Hahn, D.S. Pereira, D.S. Young</i>	520
A monoclonal antibody targeting the breast cancer stem cell marker melanoma-associated chondroitin sulfate proteoglycan improves survival and demonstrates anti-tumor activity in vivo <i>A.K. Gupta, A. Ferry, M. Amoozgar, C. Vieira, D. Sayegh, J. Menendez, N. Ceric, L.A.G. da Cruz, D.S. Pereira, D.S. Young</i>	521
Discovery of the 6F4 anti-tumor antibody targeting the tight junction molecule JAM-A. 1. Target identification by proteomic approach <i>J.F. Haeuw, L. Goetsch, L. Zanna, M. Malissard, V. Robillard, A.M. Lepecquet, A. Robert, C. Bailly, N. Corvaia</i>	522
Combination of the anti-CD30–auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma <i>H.P. Gerber, E. Oflazoglu, K. Kissler, D. Kennedy, E.L. Sievers, N.C. Ihle, D.L. Meyer, I.S. Grewal</i>	523
New biomolecule for cancer therapy <i>E. Campigna, C. Germain, S. Morisseau, J.P. Mach, A. Pèlerin, B. Robert</i>	524
Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer <i>C. Carrigan, C. Zuany-Amorim, M. Mayo, D. Tavares, R. Lutz, A. Kellogg, V. Blanc, P. Vrignaud, M. Bissery, G. Payne</i>	525
Prediction of clinical response of rituximab containing chemotherapy using newly established live-cell-imaging procedure for estimating CDC susceptibility <i>Y. Mishima, Y. Terui, N. Sugimura, Y. Mishima, K. Hatake</i>	526

Scientific programme – details	lix
Improving the therapeutic window of antibody-drug conjugates through novel linker design <i>D.L. Meyer, S.O. Doronina, T.D. Bovee, J.B. Miyamoto, M.E. Anderson, I.J. Stone, C.A. Morris-Tilden, H.P. Gerber, P.D. Senter</i>	527
Supporting MetMab entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information <i>H. Xiang, A. Reyes, M. Merchant, B. Bender, N. Jumbe, J. Young, T. Gelzleichter, A. Vaidyanathan, A. Peterson, L. Damico</i>	528
Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models <i>C.A. Vater, C. Manning, H. Millar, F. McCabe, Q. Chen, G.M. Anderson, R. Steeves, K. Lai, R.J. Lutz</i>	529
Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients <i>T. Crombet Ramos, J. Figueredo, M.T. Salomón Cárdenas, J.C. Selva Infante, C. Toledo Jiménez, J. Vaquer, N. Quintanal, S. Salva Camaño, R. Odelín Tablada, J.J. Marinello</i>	530
Junctional complexes as a factor limiting the extravascular penetration of trastuzumab <i>K.E. Lindquist, J.T. Sy, A.H. Kyle, J.H. Baker, A.I. Minchinton</i>	531
A chimerized anti-CD4 monoclonal antibody for the treatment of T cell lymphomas acts through activation of membrane acid sphingomyelinase leading to increased ceramide release and CD4/ZAP-70 protein redistribution in membrane rafts <i>M. Chentouf, M. Rigo, A. Pèlegri, T. Chardès</i>	532
In vivo stability in mice of SAR566658 (huDS6-DM4), an immunoconjugate targeting solid tumours <i>M.F. Mayo, A.P. Leung, L. Wang, P. Wunderli, G. Payne, H. Xie, R.J. Lutz</i>	533
Expression profiling demonstrates co-stimulatory activity of BMS-663513, an anti-CD137 antibody <i>H. Chang, L. Obenauer-Kutner, A.Q. He, G. Xing, A. Truong, P. Kayne, A. Flesher, N. Siemers, M. Jure-Kunkel, M. Grace</i>	534
Characterization of a fully human PDGFR α antibody that reduces tumor growth and stromal infiltration in a xenograft model of non-small cell lung cancer <i>N. Laing, B. McDermott, S. Wen, M. Pandya, A.M. Mazzola, D. Lawson, P. Hall, A. Drake, S. Klakamp, Z. Cao</i>	535
Comparison of the tumor growth inhibitory effects of tumor cell and non-tumor cell EGFR targeted antibodies in cancer models <i>D. Surguladze, M.J. Plym, I. Duignan, M. Prewett, D.J. Hicklin, Y. Wu, L. Witte, J.R. Tonra</i>	536
Detection of EGFR mutation in the sample of pleural effusion is contributive as a determinant of EGFR-TKI-therapy for the patients with lung cancer <i>A. Uchida, T. Shibayama, S. Takahashi, N. Hamada, N. Kawata, A. Tada, R. Soda, K. Takahashi</i>	537
ARH460-16-2, targeting the CD44 cancer stem cell marker, uses multiple mechanisms to achieve its therapeutic anti-cancer effects <i>L.A.G. da Cruz, K. O'Reilly, F. McConkey, X.W. Wang, T. Antoshchenko, N. Aziz, A.K. Gupta, S.E. Hahn, D.S. Pereira, D.S. Young</i>	538
Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMab <i>B. Bender, H. Xiang, A.E. Reyes II, L.A. Damico, M. Merchant, A. Peterson, W. Forrest, N.L. Jumbe</i>	539
Allogeneic MHC Class I conjugated to antitumor antibody can induce regression of syngenic tumor grafted in vivo <i>S. Morisseau, V. Cesson, P. Guillaume, E. Campigna, J.P. Mach, A. Pelegrin, B. Robert</i>	540
Gemcitabine versus combined antibodies against EGF receptors in pancreatic cancer: preclinical findings for clinical development <i>C. Larbouret, B. Robert, C. Mollevi, F. Penault-Llorca, A. Ho-Pun-Cheng, M. Coelho, I. Teulon, A. Pèlegri, D. Azria</i>	541
Vascular endothelial growth factor receptor-1 (VEGFR1) immunoreactivity in human renal carcinoma <i>S. Wang, Y. Wu, L. Witte, J. Tonra</i>	542
Location. . . location. . . location: hitting the functional epitope within the target is essential for anti-cancer antibody therapeutics <i>B.C. Mak, A.H.L. Truong, N. Feng, L.A.G. daCruz, B.S. Mistry, S.W. Fung, T. Perez, S.E. Hahn, D.S. Pereira, D.S. Young</i>	543

Discovery of the 6F4 anti-tumor antibody targeting the tight junction molecule JAM-A. 2. Target expression on human tumors and in vitro and in vivo anti-cancer activity <i>L. Goetsch, J.F. Haeuw, A. Gonzalez, C. Beau-Larvor, L. Zanna, T. Wurch, C. Bailly, N. Corvaia</i>	544
Radiation interactive agents Abstract number	
Enhancement of cell motility with radiation-induced VEGF in glioma <i>W. Kil, K. Camphausen</i>	545
GI261 brain tumor cells: responses to single or fractionated x-irradiation with the $\alpha\text{v}\beta\text{3}$ integrin thyroxine receptor antagonist TETRAC (tetraiodothyroacetic acid) <i>A. Hercbergs, P.J. Davis, M. Cieslieski, F. Davis, J.T. Leith</i>	546
Effect of the extract of <i>Taraxacum officinale</i> on inflammation induced by anti-cancer treatment <i>Y. Oh, S.H. Kang, M. Chun, E. Lee, E.H. Kim, J. Han, J. Yang</i>	547
RNA and RNA based technologies Abstract number	
Targeting non-coding promoter-associated RNAs in the c-myc gene with small interfering RNAs induce gene silencing and growth arrest in c-myc over-expressing cancer cells <i>C. Pastori, S. Napoli, M. Magistri, A. Sepe, F. Cavalli, G. Carbone, C. Catapano</i>	548
Quantitation/significance of MRD in standard risk adult ALL by RQ/PCR <i>N.K. Abousamra, D.M. Elghannam, D.A. Shahin, E.F. Goda, H. Azzam, E. Azmy, M. Salah El-Din</i>	549
Designing nanovectors for siRNA delivery: coupled experimental/modeling investigations <i>S. Pricl, P. Posocco, G.M. Pavan, M. Fermeglia, G. Scocchi, A. Danani, A. Malek, S. Napoli, C.V. Catapano</i>	550
RNAi-based identification of potential targets in colorectal cancers <i>M. Grade, A.B. Hummon, J. Camps, G. Emons, M. Spitzner, J. Gaedcke, M.J. Difilippantonio, B.M. Ghadimi, N.J. Caplen, T. Ried</i>	551
Signal transduction modulators Abstract number	
Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design <i>P.A. Janne, M. Wax, J. Leach, J. Engelman</i>	552
AP24534: an orally active kinase inhibitor that targets multiple pro-angiogenic receptors and exhibits potent anti-tumor activity in vivo <i>V.M. Rivera, R. DiRenzo, L. Berk, S. Wardwell, Y. Ning, N.I. Narasimhan, Q. Xu, W.C. Shakespeare, F. Wang, T. Clackson</i>	553
Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies <i>M.L. Rothenberg, E. Poplin, P. LoRusso, E. Yu, J. Schwartz, F. Fox, J. Mehnert, A.B. Sandler, E. Rowinsky, C.S. Higano</i>	554
The PARP inhibitor, ABT-888 overcomes resistance in temozolomide refractory breast and prostate xenograft tumors implanted in metastatic sites in vivo <i>J. Palma, L. Rodriguez, Y.W. Wang, G. Bukofzer, J. Hickson, T. Penning, V. Giranda, S. Rosenberg, D. Frost, C. Donawho</i>	555
MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models <i>M. Mark, Y. Zhang, Y. Su, M.S. Romero, C. Severin, Z. Zheng, N. Mendoza, D.W. Kaufman, G.F. Vande Woude, E. Filvaroff</i>	556
Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer <i>M.J. O'Connor, A. Lau, R.S. Finn, C. Knights, A. O'Shaughnessy, O. Kalous, D. Conklin, L. Riches, J. Carmichael, D.J. Slamon</i>	557

Scientific programme – details	lxi
Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12 <i>E.A. Kolb, C. Morton, P.J. Houghton, J.M. Maris, H.S. Friedman, S.T. Kier, R.G. Gorlick, M.H. Kang, C.P. Reynolds, M.A. Smith</i>	558
The role of the ErbB3/PI3K/AKT pathway in determining breast cancer cell sensitivity against the irreversible dual EGFR/ErbB2 inhibitor EKB-569 <i>W. Shabbir, C. Brünner-Kubarth, M. Grusch, W. Berger, B. Marian, R. Wagner, D. Lötsch, C.C. Zielinski, T.W. Grunt</i>	559
Discovery and preclinical characterization of BMS-777607: a potent, small molecule inhibitor of Met receptor tyrosine kinase <i>R. Borzilleri, J. Fargnoli</i>	560
Discovery and preclinical characterization of a series of novel JAK2 small molecule inhibitors for the treatment of myeloproliferative diseases <i>K.A. Jessen, S. Leonard, K. Froning, C. Tang, C. Smith, D. Ellis, S. Sperry, S. Gessert, S. Reich, S.G. Buchanan</i>	561
The anti-insulin-like growth factor I receptor antibody EM164 (murine AVE1642) enhances anti-tumor activity of temozolomide against neuroblastoma cell lines and xenografts <i>B. Georger, J.F. Brasme, E. Daudigeos, F. Bladt, C. Venot, L. Debussche, P. Vrignaud, G. Vassal</i>	562
SGX126: a novel, potent and highly selective small molecule inhibitor of the c-Met receptor tyrosine kinase <i>S. Buchanan, K. Jessen, C. Tang, S. Sperry, C. Smith, P. Bounaud, J. Hendle, P. Lee, S. Gessert, S. Reich</i>	563
First-in-human (FIH) study of PF-00299804 in advanced cancer patients: correlation between pharmacokinetics (PK) and pharmacodynamics (PD) <i>J. Schellens, F. Guo, P.A. Jänne, S.G. Eckhardt, D.R. Camidge, I. Taylor, J. Lucca, D.S. Boss, S.G. Wong, C.D. Britten</i>	564
Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial <i>J.S. De Bono, D.P. Petrylak, E. Calvo, F. Saad, G.R. Hudes, M.M. Cooney, M.N. Pollak, D.B. Agus, S. Gillissen, J. Scranton</i>	565
Pyrazolo[3,4-d]pyrimidines as dual kinase inhibitors of both insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor receptor family (EGFR and ErbB-2) <i>R.D. Hubbard, N.Y. Bamaung, S.D. Fidanze, S.A. Erickson, G.T. Wang, R.A. Mantei, P. Kovar, J. Wang, G.S. Sheppard, R.L. Bell</i>	566
GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models <i>A.G. Gilmartin, A.M. Kusnierz, D. Sutton, K.G. Moss, C.S. Thompson, B.L. Weber, R.A. Copeland, J.R. Jackson, S.G. Laquerre</i>	567
Selective inhibition of Met kinase activity impairs metastatic cancer cell motility and survival <i>M. Versele, T. Lavrijssen, C. Rockx, T. Geerts, B. Janssen, P. King, M. Page, T. Perera</i>	568
Preclinical studies and characterization of BMS-777607, a small molecule inhibitor of Met receptor tyrosine kinase <i>J. Fargnoli, R. Borzilleri</i>	569
Activity of IPI-926, a novel inhibitor of the HH pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHH ligand <i>J. Sydor, V. Travaglione, I. Deyneko, Z. Oaks, M. Pink, J. Proctor, M. Read, K. McGovern, V. Palombella, J. MacDougall</i>	570
Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor <i>C.E. Olsen, E.S. Gourley, X. Liu, H. Vankayalapati, D. Vollmer, P. Severson, J. Bearss, C. Jones, D.J. Bearss, S.L. Warner</i>	571
<i>Astragalus</i> saponins (AST) modulate mTOR and ERK signaling with NF-kappa B as target in native and cytokine-induced HT-29 colon cancer cells <i>J.K.S. Ko, N.L. Mok, C.M. Wong, K.K.W. Auyeung</i>	572

Identification of potent, selective JAK2 inhibitors using a fragment-based screening approach	573
<i>N.G. Wallis, G. Chessari, J.E. Curry, C. Hamlett, K.A. Lewry, J. Lyons, C.J. Richardson, D. Tisi, D. Walker, A.J. Woodhead</i>	
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway	574
<i>K. Thress, T. MacIntyre, H. Wang, Z.Y. Liu, E. Hoffmann, T. Wang, D. Whitston, J.L. Brown, K. Webster, C. Omer</i>	
Targeting metastatic tumor cell functions by inhibition of new blood vessel formation with the selective VEGF signal inhibitor, cediranib (RECENTIN™, AZD2171) or Src signaling interference using the small molecule Src inhibitor, AZD0530	575
<i>D.W. Siemann, M. Dong</i>	
ARRY-768, a highly potent and selective small-molecule PDGFR inhibitor which inhibits cellular and in vivo tumor growth	576
<i>T.C. Yeh, S. Allen, M. Callejo, A. Cox, N. Klopfenstein, S. Kragerud, M. Munson, J. Robinson, R. Woessner, F. Marmsater</i>	
Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer	577
<i>J. Miner, C. Yu, C. Iverson, R. Hamatake, W. Cheney, M. Chapman, A. Adjei, B. Quart</i>	
RGB-286638 is a novel multitargeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models	578
<i>M. Caligiuri, H. Loferer, L. Lamphere, N. Kley</i>	
Biological and biochemical activity of TLN-4601 in pancreatic cancer	579
<i>P.M. Campbell, J.J. Fiordalisi, A.B. Hanker, N. Boufaied, H. Gourdeau, P. Falardeau, A.D. Cox, C.J. Der</i>	
RhoA and RhoB inversely modulate estrogen receptor alpha expression and transcriptional activities in breast cancer cell lines	580
<i>E. Meunier, E. Malissein, E. Bouliong-Pillai, Y. Bergé, P. Balaguer, G.C. Prendergast, G. Favre, F. Dalenc, S. Doisneau-Sixou</i>	
Inhibition of protein kinase C as the molecular basis of the synergism between safingol and irinotecan in colon cancer treatment	581
<i>L. Ling, H. Lin, N. Chiu</i>	
An acquired point mutation in MEK2 causes resistance to allosteric MEK inhibitors	582
<i>A.M. Kusnierz, A.G. Gilmartin, M.R. Bleam, T.X. Vilimas, S.J. Blakemore, W.S. Halsey, K.G. Moss, D. Sutton, J.R. Jackson, S.G. Laquerre</i>	
Analysis of MAP kinase signalling pathway in KIT & PDGFRA wild-type GISTs	583
<i>O. Martinho, A. Gouveia, M. Viana-Pereira, P. Silva, A. Pimenta, R.M. Reis, J.M. Lopes</i>	
Novel inhibitors of BRAF based on a 2,6-disubstituted pyrazine scaffold	584
<i>I. Niculescu-Duvaz, E. Roman, S.R. Whittaker, F. Friedlos, R. Kirk, I.J. Scanlon, L.C. Davies, D. Niculescu-Duvaz, R. Marais, C.J. Springer</i>	
Phase I study of the safety and pharmacokinetics of an oral, film-coated (FC) tablet of CP-868,596, a PDGFR inhibitor, in patients with advanced cancers	585
<i>L. Lewis, N. Reddy, F. Guo, K.J. Pierce, A.J. Olszanski, S. Balan</i>	
Modulation of signaling through SEK1 and MKK7 differentially affects oxaliplatin sensitivity in hypoxic colon cancer cell lines	586
<i>I. Vasilevskaya, D. Roberts, M. Selvakumaran, S. Johnson, P. O'Dwyer</i>	
Understanding the role of Raf signaling in B-Raf V600E mutant versus wildtype tumors	587
<i>G. Hatzivassiliou, S. Sideris, I. Yen, S. Gloor, M. Callejo, B. Brandhuber, B. Liu, M. Belvin, S. Malek</i>	
Bench to bedside – Bedside to bench: Preclinical determination of the potential pharmacological activities of vandetanib in the clinic	588
<i>A.J. Ryan, R. Odedra, N. James, K. Ratcliffe, G. Marshall, Z. Howard, L. Jackson, D. Baker, N. Smith, S.R. Brave</i>	
Functional evaluation of members of the LIV-1 family of proteins and their role in breast cancer	589
<i>N. Mohamad Zahari, K.M. Taylor, R.I. Nicholson</i>	

Scientific programme – details lxiii

Molecular and antiproliferative effects of inhibitors of fatty acid synthase and of ErbB receptors in ovarian cancer cells 590

T.W. Grunt, R. Wagner, W. Shabbir, W. Berger, B. Marian, M. Grusch, C.C. Zielinski, R. Lupu

Antitumor activity of PLX4032, a selective V600EB-Raf inhibitor, as monotherapy and in combination with capecitabine±bevacizumab in a colorectal cancer xenograft model 591

K. Kolinsky, G. Bollag, R. Lee, K. Packman, D. Heimbrosk, F. Su, B. Higgins

Obatoclox (GX17-070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC) 592

A. Chiappori, C. Williams, D. Northfelt, J. Adams, S. Malik, M. Edelman, P. Rosen, D. Van Echo, M. Berger, E. Haura

Topoisomerase inhibitors

Abstract number

Rational design of effective therapy combining irinotecan and rapamycin to target mTOR/HIF-1 alpha axis in colon cancer 593

E. Pencreach, M. Arrive, W. Raffelsberger, I. Lelong-Rebel, A.K. Larsen, M.P. Gaub, D. Guenot, E. Guerin

Enhanced anti-tumor effects of TP300, a novel camptothecin analogue, in combination with other anti-tumor agents in human tumor xenograft models 594

M. Endo, M. Ura, H. Tanimura, K. Taniguchi, Y. Miyazaki, S. Nagao, H. Okabe, M. Miwa

First Phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules 595

D.D. Von Hoff, G. Jameson, M.J. Borad, L.S. Rosen, J. Utz, S. Dhar, L. Acosta, T. Barker, J. Walling, J.T. Hamm

The topoisomerase I inhibitor gimatecan exhibits synergistic activity with temozolomide and tyrosine kinase inhibitors in malignant glioma xenografts 596

B. Geoerger, N. Hamelin, P. Rodier, P. Opolon, R. Versace, G. Vassal

Novel Topoisomerase I mutations in colorectal carcinoma cell lines are involved in SN38 resistance 597

C. Gongora, N. Vie, S. Tuduri, A. Causse, P. Martineau, P.H. Pourquier

Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle dependent DNA damage and rapid apoptosis in cancer cell lines 598

O.K. Wong, A. Conroy, N. Tan, W. Yang, R. McDowell, J.A. Fox, R.E. Hawtin

The iron chelator di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone causes DNA damage in breast cancer cells 599

V.A. Rao, S. Klein, K. Agama, Y. Pommier, E. Shacter

Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin (B), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials 600

R. Kazerooni, C. Conrad, M.J. Johansen, M. Sakamoto, I. Fokt, C. Schroeder, N. Thapar, C. Meyer, W. Priebe, T. Madden

Vaccines

Abstract number

Cross-trial analysis of immunological and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax®) in colorectal, renal and prostate cancer patients 601

R. Harrop, W.H. Shingler, N. Drury, M. Goonewardena, J. de Belin, S. Naylor, P. Treasure

An anti-idiotypic HER2 vaccine can reverse immunological tolerance to HER2 and induce anti-tumor immunity in huHER2 female transgenic mice 602

M.Z. Ladjemi, S. Corgnac, S. Morisseau, B. Robert, C. Mollevi, T. Charès, W. Jacot, A. Pèlerin, I. Navarro-Teulon